

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2009253232 B2**

(54) Title
Polysubstituted derivatives of 6-heteroaryl-imidazo[1,2-a] pyridines, and preparation and therapeutic use thereof

(51) International Patent Classification(s)
C07D 471/04 (2006.01) **A61P 35/00** (2006.01)
A61K 31/437 (2006.01) **C07D 213/28** (2006.01)
A61P 19/00 (2006.01) **C07D 233/56** (2006.01)
A61P 25/00 (2006.01)

(21) Application No: **2009253232** (22) Date of Filing: **2009.03.20**

(87) WIPO No: **WO09/144392**

(30) Priority Data

(31) Number	(32) Date	(33) Country
0801585	2008.03.21	FR

(43) Publication Date: **2009.12.03**

(44) Accepted Journal Date: **2013.07.11**

(71) Applicant(s)
SANOFI-AVENTIS

(72) Inventor(s)
Evanno, Yannick;Rakotoarisoa, Nathalie;Machnik, David;De Peretti, Danielle

(74) Agent / Attorney
A J PARK, L 11 60 Marcus Clarke St, Canberra, ACT, 2601

(56) Related Art
WO 2008/104077 A1
WO 2008034974 A1

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international



(10) Numéro de publication internationale
WO 2009/144392 A1

(43) Date de la publication internationale
3 décembre 2009 (03.12.2009)

PCT

(51) Classification internationale des brevets :
C07D 471/04 (2006.01) A61P 25/00 (2006.01)
C07D 213/28 (2006.01) A61P 19/00 (2006.01)
C07D 233/56 (2006.01) A61P 35/00 (2006.01)
A61K 31/437 (2006.01)

Nathalie [FR/FR]; c/o Sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).

(74) Mandataire : MOREL-PECHEUX, Muriel; sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).

(21) Numéro de la demande internationale :
PCT/FR2009/000298

(81) États désignés (sauf indication contraire, pour tout titre de protection nationale disponible) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) Date de dépôt international :
20 mars 2009 (20.03.2009)

(25) Langue de dépôt : français

(26) Langue de publication : français

(30) Données relatives à la priorité :
0801585 21 mars 2008 (21.03.2008) FR

(71) Déposant (pour tous les États désignés sauf US) :
SANOFI-AVENTIS [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(84) États désignés (sauf indication contraire, pour tout titre de protection régionale disponible) : ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), européen (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventeurs; et

(75) Inventeurs/Déposants (pour US seulement) : DE PERETTI, Danielle [FR/FR]; c/o Sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). EVANNO, Yannick [FR/FR]; c/o Sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). MACHNIK, David [FR/FR]; c/o Sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR). RAKOTOARISOA,


Publiée :

— avec rapport de recherche internationale (Art. 21(3))

[Suite sur la page suivante]

(54) Title : POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF

(54) Titre : DÉRIVÉS POLYSUBSTITUÉS DE 6-HETEROARYLE-IMIDAZO[1,2- α]PYRIDINES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE



(I)

(57) Abstract : Compounds of Formula (I) (I), wherein: R₁ is a phenyl or naphthyl group, a heteroaryl group, or a heterocyclic group, optionally substituted for one or a plurality of atoms or groups; Het is a monocyclic heteroaryl group comprising 5 to 6 atoms, 1 to 3 heteroatoms of which are selected from N, O, and S; X is 1 to 3 substituents, identical to or different from each other and selected from hydrogen, halogen, (C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, NRaRb, nitro, or cyano, the (C₁-C₁₀)alkyl capable of being substituted for one or a plurality of groups selected from halogen, (C₁-C₁₀)alkoxy, (C₁-C₁₀)haloalkoxy, NRaRb, or hydroxyl; R₂, in positions 3, 5, 7, or 8 of rimidazo[1,2- α]pyridine, is 1 to 4 substituents, identical to or different from each other and selected from hydrogen, halogen, (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, or (C₁-C₁₀)alkoxy; R₃ and R₄, independently of each other, represent a hydrogen atom or a (C₁-C₁₀)alkyl group, this group being optionally substituted for an R_f group; an aryl group optionally substituted as a base or salt having an acid added. The invention is used in therapy and in synthesis methods.

(57) Abrégé :

[Suite sur la page suivante]



— avant l'expiration du délai prévu pour la modification des revendications, sera republiée si des modifications sont reçues (règle 48.2.h))

Composés de formule (I) dans laquelle : R₁ représente un groupe phényle ou naphthyle, un groupe hétéroaryle ou un groupe hétérocyclique, éventuellement substitués par un ou plusieurs atomes ou groupes; Het représente un groupe hétéroaryle monocyclique comportant de 5 à 6 atomes dont de 1 à 3 hétéroatomes choisis parmi N, O et S; X représente de 1 à 3 substituants identiques ou différents l'un de l'autre choisis parmi un hydrogène, un halogène, (C₁-C₁₀)alkyle, (C₁-C₁₀)alcoxy, NRaRb, nitro, cyano, le (C₁-C₁₀)alkyle pouvant être éventuellement substitué par un ou plusieurs groupes choisis parmi un halogène, (C₁-C₁₀)alcoxy, (C₁-C₁₀)haloalcoxy, NRaRb ou hydroxyle; R représente en position 3, 5, 7 ou 8 de rimidazo[1,2-*a*]pyridine de 1 à 4 substituants identiques ou différents l'un de l'autre choisis parmi un hydrogène, un halogène, (C₁-C₁₀)alkyle, halo(C₁-C₁₀)alkyle, (C₁-C₁₀)alcoxy; R₂ et R₃ représentent, indépendamment l'un de l'autre, un atome d'hydrogène, un groupe (C₁-C₁₀)alkyle, éventuellement substitué par un groupe Rf, ou un groupe aryle, éventuellement substitué; R₄ représente un atome d'hydrogène, un groupe (C₁-C₁₀)alkyle, éventuellement substitué par un groupe Rf; un groupe aryle, éventuellement substitué, à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique et procédé de synthèse.

2009253232 30 May 2013

WO 2009/144392


1

PCT/FR2009/000298

POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-*a*]-
PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to polysubstituted 6-heteroarylimidazo[1,2-*a*]pyridine
5 derivatives, to the preparation thereof and to their use in the manufacture of a medicament.
Also described is the therapeutic use thereof in the treatment or prevention of diseases
involving Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RN-1 and HZF3.

The subject of the present invention is the compounds of formula (I):



in which:

R₁ represents:

a phenyl or naphthyl group, a heteroaryl group or a heterocyclic group, it
being possible for these groups to be optionally substituted with one or more
15 atoms or groups chosen, independently of one another, from the following
atoms or groups: halogen, (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy,
halo(C₁-C₁₀)alkoxy, (C₁-C₁₀)thioalkyl, -S(O)(C₁-C₁₀)alkyl,
-S(O)₂(C₁-C₁₀)alkyl, hydroxyl, oxo, cyano, nitro, hydroxy(C₁-C₁₀)alkylene,
NRaRb(C₁-C₁₀)alkylene, (C₁-C₁₀)alkoxy(C₁-C₁₀)alkyleneoxy, NRaRb,
20 CONRaRb, SO₂NRaRb, NRcCORd, OC(O)NRaRb, OCO(C₁-C₁₀)alkyl,
NRcC(O)Ore, NRcSO₂Re, aryl(C₁-C₁₀)alkylene, monocyclic heteroaryl or
aryl, the monocyclic heteroaryl or aryl being optionally substituted with one
or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl,
halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl,
25 oxo, nitro, cyano or OCO(C₁-C₁₀)alkyl group, and R₁ is linked to the
imidazo[1,2-*a*]pyridine by an aromatic carbon;

Het represents a monocyclic heteroaryl group containing from 5 to 6 atoms, including from 1
to 3 heteroatoms chosen from N, O and S;

X represents from 1 to 3 substituents, which are identical to or different from one another,
30 chosen from a hydrogen, a halogen, (C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, NRaRb, nitro and cyano,

it being possible for the (C₁-C₁₀)alkyl to be optionally substituted with one or more groups chosen from a halogen, (C₁-C₁₀)alkoxy, (C₁-C₁₀)haloalkoxy, NRaRb or hydroxyl;

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen,
5 (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl and (C₁-C₁₀)alkoxy;

R₂ and R₃ represent, independently of one another,

a hydrogen atom,

a (C₁-C₁₀)alkyl group, optionally substituted with an Rf group;

an aryl group, optionally substituted with one or more substituents chosen from a

10 halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro or cyano group;

R₄ represents:

a hydrogen atom,

a (C₁-C₁₀)alkyl group, optionally substituted with an Rf group;

15 an aryl group, optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro, cyano, (C₁-C₁₀)alkyl(CO)-, CONRaRb, NRcCORd, OC(O)NRaRb, OCO(C₁-C₁₀)alkyl, NRcC(O)ORe or aryl group, the aryl being optionally substituted with one or more substituents chosen from a halogen and a
20 (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro or cyano group;

Ra and Rb represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl, aryl(C₁-C₁₀)alkylene or aryl group;

25 or Ra and Rb form, together with the nitrogen atom which bears them, an azetidine, pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted with a (C₁-C₁₀)alkyl, aryl or aryl (C₁-C₁₀)alkylene group;

Rc and Rd represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl, aryl(C₁-C₁₀)alkylene or aryl group;

30 or Rc and Rd together form a (C₂-C₅)alkylene group;

Re represents a (C₁-C₁₀)alkyl, aryl (C₁-C₁₀)alkylene or aryl group;

or Rc and Re together form a (C₂-C₅)alkylene group;

Rf represents a halogen atom or a (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, hydroxyl, cyano, NRaRb, C(O)NRaRb, NRcCORd, OC(O)NRaRb, OCO(C₁-C₁₀)alkyl, NRcCOORe,

2009253232 30 May 2013

WO 2009/144392

3

PCT/FR2009/000298

SO₂NRaRb, NRcSO₂Re, aryl(C₁-C₁₀)alkylene or aryl group, the aryl being optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro, cyano or OCO(C₁-C₁₀)alkyl group;

5 in the form of a base or of an addition salt with an acid.

The compounds of formula (I) may comprise one or more asymmetrical carbon atoms. They may therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, are part of the invention.

10 The compounds of formula (I) may exist in the form of bases or of addition salts with acids. Such addition salts are part of the invention.

The salts may be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating the compounds of formula (I) are also part of the invention.

15 The compounds of formula (I) may also exist in the form of hydrates or of solvates, i.e. in the form of associations or of combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.

The invention also provides a medicament, comprising a compound of formula (I) of the invention, or an addition salt of this compound with a pharmaceutically acceptable acid.

20 The invention also provides a pharmaceutical composition, comprising a compound of formula (I) of the invention, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

The invention also relates to a use of a compound of formula (I) of the invention, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation
25 of a medicament for use in the treatment and prevention of neurodegenerative diseases.

The invention also relates to a use of a compound of formula (I) of the invention or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of cerebral traumas and of epilepsy.

The invention also relates to a use of a compound of formula (I) of the invention, or
30 an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of psychiatric diseases.

2009253232 30 May 2013

WO 2009/144392

3a

PCT/FR2009/000298


The invention also relates to a use of a compound of formula (I) of the invention, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of inflammatory diseases.

5 The invention also relates to a use of a compound of formula (I) of the invention, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of osteoporosis and cancers.

10 The invention also relates to a use of a compound of formula (I) of the invention, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of Parkinson's disease, Alzheimer's disease, tauopathies and multiple sclerosis.


The invention also relates to a use of a compound of formula (I) of the invention, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of schizophrenia, depression, substance dependence and attention deficit hyperactivity disorders.

15 The invention also relates to a process for synthesizing the compounds of formula (I) of the invention by reacting compounds of formula (VII)



20 in which R6 represents an OPG group, R2, R3, Het, X and R are as defined above, and PG is a group protecting the hydroxyl function, with R1-Z, with R1 being as defined above and Z being a boron or tin derivative, and then deprotecting the product obtained.

The invention also relates to a process for synthesizing the compounds of formula (VII) of the invention by reacting compounds of formula (V)



in which Y is a boron derivative, and R is as defined above, with a compound of formula (VI)


30 May 2013

2009253232

WO 2009/144392


3b

PCT/FR2009/000298




in which R6 represents an OPG group, R2, R3, Het and X are as defined above, and PG is a group protecting the hydroxyl function

The invention also relates to a process for synthesizing the compounds of formula (I) by reacting compounds of formula (II)




in which R and R1 are as defined above, and Y is a boron derivative, with a compound of formula (III)




10 in which R5 represents a group and R2, R3, R4, Het and X are as defined above and Z is a halogen.

The invention also relates to a process for synthesizing the compounds of general formula (I) of the invention, wherein an aminopyridine of general formula (XI),



15 in which R2, R3, R4, Het and X are defined above, and R6 represents R4, is reacted with a bromoketone of general formula (XII),



in which R1 is defined above and R represents a hydrogen atom or a (C₁-C₁₀)alkyl group.

2009253232 30 May 2013


WO 2009/144392

3c


PCT/FR2009/000298

The invention also relates to a process for synthesizing the compounds of general formula (I) of the invention, wherein:


a) an aminopyridine of general formula (XI),



- 5 in which R2, R3, R4, Het and X are defined above, and R6 represents R4, is reacted with a bromoketone of general formula (XII),



in which R1 is defined above and R represents a hydrogen atom or a (C₁-C₁₀)alkyl group, so as to obtain a compound of general formula (XIII)



in which R6 represents a group PG protecting the hydroxyl function;

b) the compound of general formula (XIII) obtained in step a) is subjected to a deprotection reaction.









2009253232 30 May 2013

WO 2009/144392


3d

PCT/FR2009/000298

The invention also provides a compound selected from:



and



















WO 2009/144392

3e

PCT/FR2009/000298

The invention also relates to a synthesis process of the invention, wherein the compounds of general formulae (II), (V), (VII) and (X) are the compounds of general formulae (II-1), (II-2), (II-3), (II-4), (II-5), (II-6), (II-7), (V-1), (VII-1), (VII-2), (VII-3), (VII-4), (X-1), (X-2), (X-3) and (X-4)



- the term "a haloalkoxy group" is intended to mean: an -O- alkyl radical where the alkyl group is as defined above and substituted with one or more halogen atoms, which are identical or different. By way of examples, mention may be made of OCF₃, OCHF₂ or OCCl₃ groups;
- 5 - the term "a thioalkyl group" is intended to mean: an S-alkyl group where the alkyl group is as defined above;
- the term "an aryl group" is intended to mean: a monocyclic or bicyclic aromatic group containing from 6 to 10 atoms. By way of examples of an aryl group, mention may be made of phenyl and naphthyl groups;
- 10 - the term "a heteroaryl group" is intended to mean: a monocyclic or bicyclic aromatic group containing from 5 to 10 atoms, including from 1 to 4 heteroatoms chosen from N, O and S. By way of examples of heteroaryl groups, mention may be made of: pyrrole, furane, thiophene, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyrimidine, pyrazine, pyridazine,
- 15 triazine, thienothiophene, furofuran, thienofuran, furopyrrole, thienopyrrole, pyrrolopyrrole, pyrroloisoxazole, furoisoxazole, thienoisoxazole, isoxazoloisoxazole, pyrrolooxazole, furooxazole, thienooxazole, oxazoloisoxazole, oxazolooxazole, pyrroloisothiazole, furoisothiazole, thienoisothiazole, isothiazoloisoxazole, isothiazolooxazole, isothiazoloisothiazole, pyrrolothiazole, furothiazole, thienothiazole,
- 20 thiazolooxazole, thiazoloisoxazole, thiazoloisothiazole, thiazolothiazole, pyrrolopyrazole, furopyrazole, thienopyrazole, pyrazoloisoxazole, pyrazolooxazole, pyrazoloisothiazole, pyrazolothiazole, pyrazolopyrazole, pyrroloimidazole, furoimidazole, thienoimidazole, imidazoisoxazole, imidazooxazole, imidazoisothiazole, imidazothiazole, imidazopyrazole, imidazoimidazole, pyrrolooxadiazole,
- 25 furooxadiazole, thienooxadiazole, pyrazolooxadiazole, imidazooxadiazole, furothiadiazole, thienothiadiazole, pyrrolothiadiazole, imidazothiadiazole, pyrazolothiadiazole, thienotriazole, pyrrolotriazole, furotriazole, oxazolotriazole, isoxazolotriazole, thiazolotriazole, isothiazolotriazole, pyrazolotriazole, imidazotriazole, indole, isoindole, benzimidazole, indazole, indolizine, benzofuran, isobenzofuran,
- 30 benzothiophene, benzo[c]thiophene, pyrrolopyridine, imidazopyridine, pyrazolopyridine, triazolopyridine, tetrazolopyridine, pyrrolopyrimidine, imidazopyrimidine, pyrazolopyrimidine, triazolopyrimidine, pyrrolopyrazine, imidazopyrazine, pyrazolopyrazine, triazolopyrazine, pyrrolopyridazine, imidazopyridazine, pyrazolopyridazine, triazolopyridazine, pyrrolotriazine,

imidazotriazine, pyrazolotriazine, furopyridine, fuopyrimidine, fuopyrazine, fuopyridazine, furotriazine, oxazolopyridine, oxazolopyrimidine, oxazolopyrazine, oxazolopyridazine, isoxazolopyridine, isoxazolopyrimidine, isoxazolopyrazine, isoxazolopyridazine, oxadiazolopyridine, benzoxazole, benzisoxazole, benzoxadiazole, thienopyridine, thienopyrimidine, thienopyrazine, thienopyridazine, thienotriazine, thiazolopyridine, thiazolopyrimidine, thiazolopyrazine, thiazolopyridazine, isothiazolopyridine, isothiazolopyrimidine, isothiazolopyrazine, isothiazolopyridazine, thiadiazolopyridine, benzothiazole, benzoisothiazole, benzothiadiazone, benzotriazole, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline, quinazoline, naphthyridine, benzotriazine, pyridopyrimidine, pyridopyrazine, pyridopyridazine, pyridotriazine, pyrimidopyrimidine, pyrimidopyrazine, pyrimidopyridazine, pyrazinopyrazine, pyrazinopyridazine, pyridazinopyridazine.

- the term "a heterocyclic group" is intended to mean: a bicyclic group containing from 9 to 10 atoms comprising from 1 to 4 heteroatoms chosen from N, O and S, one ring of which is aromatic and the other ring of which is saturated or partially saturated, each of the rings comprising at most only 2 heteroatoms. By way of examples of bicyclic groups, mention may be made of: benzodioxole, benzoxathiole, benzopyran, benzothiopyran, benzoxazine, benzothiazine, benzodioxine, benzothioxine, dioxolopyridine, oxathiolo-pyridine, pyranopyridine, thiopyranopyridine, oxazinopyridine, thiazinopyridine, dioxinopyridine, thioxinopyridine, dioxolopyrimidine, oxathiolopyrimidine, pyranopyrimidine, thiopyranopyrimidine, oxazinopyrimidine, thiazinopyrimidine, dioxinopyrimidine, thioxinopyrimidine, dioxolopyrazine, oxathiolopyrazine, pyranopyrazine, thiopyranopyrazine, oxazinopyrazine, thiazinopyrazine, dioxinopyrazine, thioxinopyrazine, dioxolopyridazine, oxathiolopyridazine, pyranopyridazine, thiopyranopyridazine, oxazinopyridazine, thiazinopyridazine, dioxinopyridazine, thioxinopyridazine, indole, isoindole, benzimidazole, indazole, indolizine, benzofuran, isobenzofuran, benzothiophene, benzo[c]thiophene, pyrrolopyridine, imidazopyridine, pyrazolopyridine, pyrrolopyrimidine, imidazopyrimidine, pyrazolopyrimidine, pyrrolopyrazine, imidazopyrazine, pyrazolopyrazine, pyrrolopyridazine, imidazopyridazine, pyrazolopyridazine, furopyridine, fuopyrimidine, fuopyrazine, fuopyridazine, oxazolopyridine, oxazolopyrimidine, oxazolopyrazine, oxazolopyridazine, isoxazolopyridine, isoxazolopyrimidine, isoxazolopyrazine, isoxazolopyridazine, benzoxazole, benzisoxazole, benzoxadiazole, thienopyridine, thienopyrimidine,

- thienopyrazine, thienopyridazine, thiazolopyridine, thiazolopyrimidine, thiazolopyrazine, thiazolopyridazine, isothiazolopyridine, isothiazolopyrimidine, isothiazolopyrazine, isothiazolopyridazine, benzothiazole, benzoisothiazole, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline, quinazoline, naphthyridine, pyridopyrimidine, pyridopyrazine, pyridopyridazine, pyrimidopyrimidine, pyrimidopyrazine, pyrimidopyridazine, pyrazinopyrazine, pyrazinopyridazine, pyridazinopyridazine, one of the rings of these bicyclic groups being in saturated or partially saturated form, for example dihydrobenzofuran, tetrahydroquinoline, dihydrobenzoxazole or benzodioxole;
- 10 - the sulphur and nitrogen atoms may be in the oxidized state (N-oxide, sulphoxide, sulphone).

Among the compounds of formula (I) which are subjects of the invention, a first group of compounds is constituted of the compounds for which:

- 15 R_1 represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl, thienyl, benzofuranyl, benzothiazolyl, benzothieryl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more groups or atoms chosen, independently of one another, from halogen, (C_1-C_{10}) alkyl, (C_1-C_{10}) alkoxy, $CONRaRb$, $NRaRb$, (C_1-C_{10}) thioalkyl, 20 $-S(O)_2(C_1-C_{10})$ alkyl, halo (C_1-C_{10}) alkyl, hydroxy (C_1-C_{10}) alkylene, $NRaRb(C_1-C_{10})$ alkylene, $NRcCORd$, SO_2NRaRb , cyano and nitro;

Ra and Rb represent, independently of one another, a hydrogen atom or a (C_1-C_{10}) alkyl group;

- or Ra and Rb form, together with the nitrogen atom which bears them, an azetidine, 25 pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted with a (C_1-C_{10}) alkyl, aryl or aryl (C_1-C_{10}) alkylene group;

Rc and Rd represent, independently of one another, a hydrogen atom or a (C_1-C_{10}) alkyl group;

- 30 the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, a second group of compounds is constituted of the compounds for which:

- R_1 represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl, thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more groups or atoms chosen, independently of one another, from halogen, (C_1-C_{10}) alkyl, (C_1-C_{10}) alkoxy, $CONRaRb$, $NRaRb$, (C_1-C_{10}) thioalkyl, $-S(O)_2(C_1-C_{10})$ alkyl, halo (C_1-C_{10}) alkyl, hydroxy (C_1-C_{10}) alkylene, $NRaRb(C_1-C_{10})$ alkylene, $NRcCORd$, SO_2NRaRb , cyano and nitro;
- Ra and Rb represent, independently of one another, a hydrogen atom or a (C_1-C_{10}) alkyl group;
- Rc and Rd represent, independently of one another, a hydrogen atom or a (C_1-C_{10}) alkyl group;
- the other substituents being as defined above.

- Among the compounds of formula (I) which are subjects of the invention, a third group of compounds is constituted of the compounds for which:

- R_1 represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl, thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more atoms or groups chosen, independently of one another, from halogen, methyl, methoxy, hydroxymethyl, $CON(CH_3)_2$, morpholinyl, pyrrolidinylethyl, $NHCO-CH(CH_3)_2$, $CH_2N(CH_3)_2$, NH_2 , $CONHCH(CH_3)_2$, pyrrolidinyl, methylsulphonyl, trifluoromethyl, methylthio, cyano, nitro, $-NHCO(CH_3)$, $CONH(CH_3)$, $CONHC(CH_3)_3$, $-SO_2N(CH_3)_2$ and *isopentyl*;
- the other substituents being as defined above.

25

- Among the compounds of formula (I) which are subjects of the invention, a fourth group of compounds is constituted of the compounds for which:

Het represents a furyl, thienyl, pyridinyl, thiazolyl, pyrazolyl or imidazolyl group;

the other substituents being as defined above.

30

- Among the compounds of formula (I) which are subjects of the invention, a fifth group of compounds is constituted of the compounds for which:

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen and (C₁-C₁₀)alkyl groups;
the other substituents being as defined above.

5 Among the compounds of formula (I) which are subjects of the invention, a sixth group of compounds is constituted of the compounds for which:

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a fluorine and a methyl group;
the other substituents being as defined above.

10

Among the compounds of formula (I) which are subjects of the invention, a seventh group of compounds is constituted of the compounds for which:

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 substituents, which are identical to or different from one another, chosen from a hydrogen and

15 (C₁-C₁₀)alkyl;

the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, an eighth group of compounds is constituted of the compounds for which:

20 R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 hydrogen atoms, or 1 methyl group;

the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, a ninth group of compounds is constituted of the compounds for which:

25 R represents, at position 3 of the imidazo[1,2-*a*]pyridine, 1 hydrogen atom or 1 methyl group;

the other substituents being as defined above.

30 Among the compounds of formula (I) which are subjects of the invention, a tenth group of compounds is constituted of the compounds for which:

R₂ and R₃ represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, an eleventh group of compounds is constituted of the compounds for which:

- 5 R_2 and R_3 represent, independently of one another, a hydrogen atom or a methyl group;
the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, a twelfth group of compounds is constituted of the compounds for which:

- 10 R_4 represents: a hydrogen atom or a (C₁-C₁₀)alkyl group;
the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, a thirteenth group of compounds is constituted of the compounds for which:

- 15 R_4 represents: a hydrogen atom or a methyl group;
the other substituents being as defined above.

Among the compounds of formula (I) which are subjects of the invention, a fourteenth group of compounds is constituted of the compounds for which:

- 20 R_1 represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl, thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more atoms or groups chosen, independently of one another, from halogen, (C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, -CONRaRb, -NRaRb,
25 (C₁-C₁₀)thioalkyl, -S(O)₂(C₁-C₁₀-alkyl), halo(C₁-C₁₀)alkyl, hydroxy(C₁-C₁₀)alkylene, NRaRb(C₁-C₁₀)alkylene, NRcCORd, SO₂NRaRb, cyano and nitro;

Ra and Rb represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

or Ra and Rb form, together with the nitrogen atom which bears them, an azetidine,
30 pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted with a (C₁-C₁₀)alkyl, aryl or aryl(C₁-C₁₀)alkylene group;

Rc and Rd represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

Het represents a furyl, thienyl, pyridinyl, thiazolyl, pyrazolyl or imidazolyl group;

5 X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen and (C₁-C₁₀)alkyl groups;

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen and (C₁-C₁₀)alkyl;

10 R₂ and R₃ represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

R₄ represents: a hydrogen atom or a (C₁-C₁₀)alkyl group;
in the form of a base or of an addition salt with an acid.

15 Among the compounds of formula (I) which are subjects of the invention, a fifteenth group of compounds is constituted of the compounds for which:

R₁ represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl, thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more groups or atoms chosen, independently of one
20 another, from halogen, (C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, CONRaRb, NRaRb, (C₁-C₁₀)thioalkyl, -S(O)₂(C₁-C₁₀-alkyl), halo(C₁-C₁₀)alkyl, hydroxy(C₁-C₁₀)alkylene, NRaRb(C₁-C₁₀)alkylene, NRcCORd, SO₂NRaRb, cyano and nitro;

Ra and Rb represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

25 Rc and Rd represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

Het represents a furyl, thienyl, pyridinyl, thiazolyl, pyrazolyl or imidazolyl group;

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen and (C₁-C₁₀)alkyl groups;

30 R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen and (C₁-C₁₀)alkyl;

R₂ and R₃ represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

R₄ represents: a hydrogen atom or a (C₁-C₁₀)alkyl group;
in the form of a base or of addition salt with an acid.

Among the compounds of formula (I) which are subjects of the invention, a sixteenth group
5 of compounds is constituted of the compounds for which:

R₁ represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl,
thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl,
pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups
to be optionally substituted with one or more atoms or groups chosen, independently of one
10 another, from halogen, methyl, methoxy, hydroxymethyl, -CON(CH₃)₂, morpholinyl,
pyrrolidinylethyl, -NHCO-CH(CH₃)₂, -CH₂N(CH₃)₂, -NH₂, -CONHCH(CH₃)₂, pyrrolidinyl,
methylsulphonyl, trifluoromethyl, methylthio, cyano, nitro, -NHCO(CH₃), CONH(CH₃),
CONHC(CH₃)₃, -SO₂N(CH₃)₂ and *isopentyl*;

Het represents a furyl, thienyl, pyridinyl, thiazolyl, pyrazolyl or imidazolyl group;

15 X represents from 1 to 3 substituents, which are identical to or different from one another,
chosen from a hydrogen, a fluorine and a methyl group;

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 hydrogen
atoms or methyl groups;

R₂ and R₃ represent, independently of one another, a hydrogen atom or a methyl group;

20 R₄ represents: a hydrogen atom or a methyl group;
in the form of a base or of an addition salt with an acid.

Among the compounds of formula (I) which are subjects of the invention, a seventeenth
group of compounds is constituted of the compounds for which:

25 R₁ represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl,
thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl,
pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups
to be optionally substituted with one or more atoms or groups chosen, independently of one
another, from halogen, methyl, methoxy, hydroxymethyl, -CON(CH₃)₂, morpholinyl,
30 pyrrolidinylethyl, -NHCO-CH(CH₃)₂, -CH₂N(CH₃)₂, -NH₂, -CONHCH(CH₃)₂, pyrrolidinyl,
methylsulphonyl, trifluoromethyl, methylthio, cyano, nitro, -NHCO(CH₃), CONH(CH₃),
CONHC(CH₃)₃, -SO₂N(CH₃)₂ and *isopentyl*;

Het represents a furyl, thienyl, pyridinyl, thiazolyl, pyrazolyl or imidazolyl group;

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a fluorine and a methyl group;

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 hydrogen atoms, or 1 methyl group;

5 R₂ and R₃ represent, independently of one another, a hydrogen atom or a methyl group;

R₄ represents: a hydrogen atom or a methyl group;

in the form of a base or of an addition salt with an acid.

10 Among the compounds of formula (I) which are subjects of the invention, an eighteenth group of compounds is constituted of the compounds for which:

R₁ represents a phenyl, furyl or quinolinyl group, it being possible for these groups to be optionally substituted with one or more atoms or groups chosen, independently of one another, from halogen and (C₁-C₁₀)alkyl;

Het represents a furyl group, a thienyl group, a pyridinyl group or a thiazolyl group;

15 X represents a hydrogen;

R is a hydrogen;

R₂ and R₃ represent, independently of one another, a hydrogen atom;

R₄ represents a hydrogen atom,

in the form of a base or of an addition salt with an acid.

20

Among the compounds of formula (I) which are subjects of the invention, mention may in particular be made of the following compounds:

- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {2-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-3-yl}methanol;
- {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {6-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-2-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-3-yl}methanol;

- {2-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-5-yl}methanol;
- {2-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-4-yl}methanol;
- {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [2-(2-Furan-3-ylimidazo[1,2-*a*]pyridin-6-yl)pyridin-4-yl]methanol and the hydrochloride thereof;
- [5-(2-Quinolin-3-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol and the hydrochloride thereof;
- [4-(2-*p*-Tolylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [2-(2-Quinolin-3-ylimidazo[1,2-*a*]pyridin-6-yl)pyridin-4-yl]methanol and the hydrochloride thereof;
- [4-(2-Quinolin-3-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol and the hydrochloride thereof;
- {4-[2-(1*H*-Indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {5-[2-(1*H*-Indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol and the hydrochloride thereof;
- [4-(2-Phenylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol and the hydrochloride thereof;
- {4-[2-(1*H*-Pyrrolo[2,3-*i*]pyridin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol and the hydrochloride thereof;
- {4-[2-(3-Methoxyphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol and the hydrochloride thereof;
- {2-[2-(1*H*-Pyrrolo[2,3-*b*]pyridin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}methanol and the hydrochloride thereof;
- [2-(2-Phenylimidazo[1,2-*a*]pyridin-6-yl)pyridin-4-yl]methanol;
- [5-(2-*p*-Tolylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Phenylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(3-Methoxyphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;

- {5-[2-(2,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-3-yl}methanol;
- 2-(4-Chlorophenyl)-6-(4-methoxymethyl-furan-2-yl)imidazo[1,2-*a*]pyridine;
- {5-[2-(4-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- 4-[6-(5-Hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {5-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(2-Methoxypyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Quinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Morpholin-4-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Isoquinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- (5-{2-[4-(1-Pyrrolidin-1-ylethyl)phenyl]imidazo[1,2-*a*]pyridin-6-yl}furan-2-yl)methanol;
- 4-[6-(5-Hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {4-[2-(2-Methoxypyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Isoquinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- *N*-{3-[6-(5-Hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl}isobutyramide;
- (4-{2-[4-(1-Pyrrolidin-1-ylethyl)phenyl]imidazo[1,2-*a*]pyridin-6-yl}thien-2-yl)methanol;
- {4-[2-(4-Dimethylaminomethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- 2-Fluoro-4-[6-(5-hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {4-[2-(3-Aminophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- *N*-tert-Butyl-5-[6-(5-hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-

yl]nicotinamide;

- [5-(3-Methyl-2-phenylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(3-Methyl-2-thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(3-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Pyrrolidin-1-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- 3-[6-(5-Hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]benzonitrile;
- [5-(2-Benzofuran-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzothiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzo[*b*]thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {4-[2-(4-Nitrophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Thien-3-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(4-Methylthiophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(5-Chlorothien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(4-Methylsulphonylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Benzo[*b*]thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Benzo[*b*]thien-5-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(3-Methyl-2-phenylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(3-Methyl-2-thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(4-Methoxyphenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Pyrrolidin-1-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Methylsulphonylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Benzofuran-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Benzo[*b*]thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;

- [4-(2-Furan-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Benzo[*b*]thien-5-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(4-Pyrrolidin-1-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- 1-{4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}ethanol;
- 2-{4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}propan-2-ol;
- {5-[2-(4-Methoxyphenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Trifluoromethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Methoxyphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(3,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Thien-3-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(5-Chlorothien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(3-Bromophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Chloro-3-methylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Methylsulphonylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzofuran-3-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(2,3-Dihydrobenzofuran-5-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Furan-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzofuran-5-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Thiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(4-Methylthiophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {4-[2-(4-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;


- [4-(3-Methyl-2-thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(3-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(2,4-Difluorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(4-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(3,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- 3-[6-(5-Hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]benzonitrile;
- {4-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(3-Bromophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Benzofuran-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Benzofuran-3-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(1-Methyl-1*H*-benzimidazol-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(2,3-Dihydrobenzofuran-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Furan-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Benzofuran-5-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Thiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(4-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(3-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Trifluoromethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(3,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;

- [4-(2-Thien-3-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Pyridin-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(5-Chlorothien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(3-Bromophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(4-Chloro-3-methylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- [4-(2-Thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Benzofuran-3-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(2,3-Dihydrobenzofuran-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- [4-(2-Benzofuran-5-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Thiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {5-[2-(3-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl} methanol;
- *N*-{3-[6-(5-Hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl} isobutyramide;
- 2-Fluoro-4-[6-(5-hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- 2-{4-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}propan-2-ol;
- *N*-{3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl} acetamide;
- {4-[2-(4-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(3-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(1*H*-Indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(4-Methylthien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(1*H*-Indol-4-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(2-Fluoropyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;

- 3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {4-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(2-Methoxypyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- 4-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N*-methylbenzamide;
- {4-[2-(4-Methylthien-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(1-Methyl-1*H*-indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Quinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- *N*-{4-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl}acetamide;
- {4-[2-(4-Morpholin-4-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Isoquinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- *N*-{3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl}isobutyramide;
- 3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzenesulphonamide;
- {4-[2-(2,6-Difluoropyridin-4-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- (4-{2-[1-(3-Methylbutyl)-1*H*-pyrazol-4-yl]imidazo[1,2-*a*]pyridin-6-yl}thiazol-2-yl)methanol;
- 2-{4-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]-1*H*-pyrazol-3-yl}propan-2-ol;
- 2-{5-Fluoro-2-[2-(1*H*-indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- 2-{2-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- 2-{2-[2-(1*H*-Indazol-3-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- 2-{2-[2-(5-Methylisoxazol-3-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;

- {5-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]-1-methyl-1*H*-imidazol-2-yl} methanol;
- 2-{5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl} propan-2-ol.

In accordance with the invention, the compounds of general formula (I) can be prepared according to the process described in Scheme 1.



Scheme 1

The compounds of the invention can be prepared according to Scheme 1 (pathway A) by means of a coupling reaction, catalysed by a metal such as palladium, between an imidazopyridine of general formula (II), in which R and R1 are defined as above and Y represents a halogen atom or a boron derivative, and a derivative of general formula (III) in which Het and X are defined as above, Z represents a boron or tin derivative if Y represents a halogen atom, or else a halogen atom if Y represents a boron derivative, and R5 represents

the group  so as to obtain the compounds of general formula (I), for example, according to the method described by A. Gueiffier in *Helv. Chim. Acta* 2001, **84**, 3610-3615.


The compounds of the invention can also be prepared according to Scheme 1 (pathway A') by means of a coupling reaction, catalysed by a metal such as palladium, between an imidazopyridine of general formula (II), in which R and R1 are defined as above and Y represents a halogen atom or a boron derivative, and a derivative of general formula (III'), in which Het and X are defined as above, Z represents a boron or tin derivative if Y

represents a halogen atom, or else a halogen atom if Y represents a boron derivative, and R5' represents a carbonylated derivative R2CO, in which R2 is defined as above, or represents a CO₂-alkyl group, so as to obtain the compounds of general formula (IV), for example, according to the method described by A. Gueiffier in *Helv. Chim. Acta* 2001, 84, 3610-3615.

Next, the compounds of general formula (IV) can be converted to compounds of general formula (I), in which R4 represents a hydrogen atom, through the action of an organometallic derivative such as an organomagnesium compound, for example R₃MgBr, in which R3 is defined as above, or by reduction of the carbonyl group by means of a metal hydride, for example sodium borohydride or a derivative thereof, or any other method known to those skilled in the art.

In Scheme 1, the starting compounds and the reactants, when the method for preparing them is not described, are commercially available or described in the literature, or else can be prepared according to methods which are described therein or which are known to those skilled in the art. In particular, the imidazopyridines of general formula (II), in which Y represents a boron derivative, can be obtained, for example, according to the method described by E. DiMauro in *J. Org. Chem.* 2006, 71, 3959.

In accordance with the invention, the compounds of general formula (I) can also be prepared according to the process described in Scheme 2.



Scheme 2


The compounds of the invention can be prepared according to Scheme 2 by means of a coupling reaction, catalysed by a metal such as palladium, between an imidazopyridine of general formula (VII), in which Het, R, X, R2 and R3 are defined as above and R6 represents the group OR4, and a derivative of general formula (VIII), in which R1 is defined as above and Z represents a boron or tin derivative, so as to obtain the compounds of general formula (I), for example, according to the method described by S. Buchwald in *J.A.C.S.* 2005, 127, 4685.

The compounds of the invention can also be prepared according to Scheme 2 by means of a coupling reaction, catalysed by a metal such as palladium, between an imidazopyridine of general formula (VII), in which Het, R, X, R2 and R3 are defined as above and R6 represents OPG, in which PG represents a group protecting hydroxyl, as described, for example, by T. Greene in "*Protective Groups in Organic Synthesis*" (Wiley Interscience), and a derivative of general formula (VIII), in which R1 is defined as above and Z represents a boron or tin derivative, so as to obtain the compounds of general formula (IX), for example, according to the method described by S. Buchwald in *J.A.C.S.* 2005, 127, 4685. Next, the compounds of general formula (IX) can be converted to compounds of general formula (I), in which R4 represents a hydrogen atom, by carrying out a deprotection reaction as described, for example, by T. Greene in "*Protective Groups in Organic Synthesis*" (Wiley Interscience), or by any method known to those skilled in the art.

The imidazopyridines of general formula (VII) can be obtained by means of a coupling reaction, catalysed by a metal such as palladium, between an imidazopyridine of general formula (V), in which R is defined as above and Y represents a boron derivative, and a derivative of general formula (VI), in which Het, R2, R3 and X are defined as above, R6 represents the group OR4 or a group OPG, in which PG represents a group protecting hydroxyl, and Hal represents a halogen atom other than chlorine, so as to obtain the compounds of general formula (VII), for example, according to the method described by A. Gueiffier in *Helv. Chim. Acta* 2001, 84, 3610-3615.

In Scheme 2, the starting compounds and the reactants, when the method for preparing them is not described, are commercially available or described in the literature, or else can be prepared according to methods which are described therein or which are known to those skilled in the art. In particular, the chlorinated imidazopyridines of general formula (V) can be obtained, for example, according to the method described by C. Townsend in *Syn. Commun.* 1997, 27, 1763-1765.

In accordance with the invention, the compounds of general formula (I), in which R represents a hydrogen atom or an alkyl group in the 3-position with respect to the imidazopyridine nucleus, can also be prepared according to the process described in Scheme 3.



Scheme 3

The compounds of the invention can be prepared according to Scheme 3 by means of a condensation reaction between an aminopyridine of general formula (XI), in which R_2 , R_3 and X are defined as above, and R_6 represents R_4 or a hydroxyl function-protecting group PG, and a bromoketone of general formula (XII), in which R_1 is defined as above and R represents a hydrogen atom or an alkyl group, so as to obtain either an imidazopyridine of general formula (I), in which R , R_1 , R_2 , R_3 , R_4 and X are defined as above, or an imidazopyridine of general formula (XIII), in which R_6 represents PG, for example according to the method described by M. Fisher in *J. Med. Chem* 1972, 15, 982. As hydroxyl function protecting group, mention may be made of those described, for example, by T. Greene in "Protective Groups in Organic Synthesis" (Wiley Interscience), for example a tert-butyldimethylsilyl group.

Moreover, when R_6 represents a hydroxyl function-protecting group PG, the compounds of general formula (XIII) are subjected to a deprotection reaction, as described, for example, by T. Greene in "Protective Groups in Organic Synthesis" (Wiley Interscience), so as to obtain the compounds of general formula (I), in which R is in the 3-position with respect to the imidazopyridine nucleus and R_4 represents a hydrogen atom.

2009253232 30 May 2013

WO 2009/144392

24

PCT/FR2009/000298

















The compounds of general formula (XI) can be obtained by means of a coupling reaction, catalysed by a metal such as palladium, between a halogenated derivative of general formula (X), in which R₂, R₃, X and Hal are defined as above, and R₆ represents R₄ or a hydroxyl function-protecting group PG, and a 2-aminopyridine substituted with a group Z which represents a boron or tin derivative, such as, for example, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine.

In general, the above intermediates can be subjected, if desired and if necessary, to any protection/deprotection reactions known to those skilled in the art before and/or after any reactions described in the schemes above.

The products of formula (I) can be subjected, if desired and if necessary, to any reactions known to those skilled in the art, in any order, in order to be converted into other products of formula (I).

By way of examples of reactions, mention may be made of: reactions for esterification or amidation of an acid function, carbamoylation reactions, ester function hydrolysis reactions, reactions for conversion of a hydroxyl function to an alkoxyl function, coupling reactions catalysed by a transition metal, reactions for protecting reactive functions, reactions for removing the protective groups that the protected reactive functions may bear, salification reactions with an inorganic or organic acid or with a base so as to obtain the corresponding salt, reactions for resolving racemic forms into enantiomers, said products of formula (I) thus obtained being, where appropriate, in all the possible racemic, enantiomeric and diastereoisomeric isomer forms.

According to another of its aspects, a subject of the invention is also the compounds of formulae (II-7), (VII-1), (VII-2), (VII-3), (VII-4), (X-1), (X-2) and (X-3) and (X4). Also described are the compounds of formulae (II-1), (II-2), (II-3), (II-4), (II-5), (II-6) and (V-1). These compounds are of use as synthesis intermediates of the compounds of formula (I).



The compounds of formulae (II-1), (II-2), (II-3), (II-4), (II-5), (II-6) and (II-7) can be prepared in one stage (boronic esters) or two stages (boronic acids), for example according to the process described in Examples No. 2 and No. 6. In a first stage, a condensation can be carried out between an aminopyridine substituted with a boron derivative, such as, for example, a 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine, and an alpha-bromoketone, such as a 2-bromo-1-(aryl)ethanone, for example in a solvent such as n-propanol, in the presence of a base such as, for example, sodium hydrogen carbonate, so as to obtain the corresponding boronate esters. Next, in a second stage, the boronic esters are hydrolysed to the corresponding boronic acids, for example in a mixture of acetone, water and hydrochloric acid.

The compound of formula (V-1) can be prepared, for example, according to the process described in Example No. 3. In a first stage, a condensation can be carried out between an aminopyridine substituted with a boron derivative, such as, for example, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine, and ethyl 2-bromoacetate. In a second stage, the compound is subjected to a reaction of cyclisation and of chlorination in the presence of a chlorinating agent such as phosphorus oxychloride, which gives the compound (V-1).

The compounds of formulae (VII-1), (VII-2), (VII-3) and (VII-4) can be prepared by means of a coupling reaction, catalysed by a metal such as palladium, between, for example, the compound (V-1) and a halogenated, for example brominated, heterocycle comprising a protected alcohol function, for example protected with a tert-butyldimethylsilyl group, as described in Examples No. 3 and 4.

The compounds of formulae (X-1), (X-2), (X-3) and (X-4) can be prepared by condensation between an aminopyridine substituted with a boron derivative, such as, for example, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine, and a halogenated, for example, borominated, heterocycle comprising a protected alcohol function, for example protected with a tert-butyldimethylsilyl or trimethylsilyl group, for example according to the process described in Examples No. 5, 6 and 7.

The compounds of formulae (II-1), (II-2), (II-3), (II-4), (II-5), (II-6), (V-1), (VII-1), (VII-2), (VII-3), (VII-4), (X-1), (X-2), (X-3) and (X-4) were prepared in the form of a powder or of an oil, in the form of a base or of an addition salt with an acid. Table 1 gives some physicochemical data of these intermediates.

In this table, in the "salt/base" column, "-" represents a compound in free base form, whereas "HCl" represents a compound in hydrochloride form, and the ratio between parentheses is the (acid:base) ratio.

5

Table 1

No.	¹ H NMR (DMSO-d ₆ , δ ppm); M+H; Mp	Salt/base
(II-1)	1.35 (s, 12H); 7.35 (d, 1H); from 7.5 to 7.6 (m, 3H); 7.95 (d, 2H); 8.45 (d, 1H); 7.85 (s, 1H). M+H = 355.	-
(II-2)	1.45 (s, 12H); 2.45 (s, 3H); 7.3 (d, 2H); from 7.5 to 7.7 (m, 2H); from 7.85 to 8 (m, 3H); 8.6 (s, 1H); M+H = 335	-
(II-3)	From 7.6 to 7.75 (m, 2H); 7.95 (m, 1H); from 8.05 to 8.15 (m, 2H); 8.2 (m, 1H); 8.9 (s, 1H); 9.1 (s, 1H). M+H = 273.	HCl (1:1)
(II-4)	7.55 (m, 1H); 7.6 (m, 2H); 8.0 (m, 1H); 8.1 (m, 2H); 8.25 (d, 1H); 8.9 (s, 1H); 9.1 (s, 1H). M+H = 275	HCl (1:1)
(II-5)	3.75 (s, 3H); 6.95 (d, 1H); from 7.3 to 7.65 (m, 3H); 7.8 (d, 1H); 8.05 (d, 1H); 8.75 (s, 1H); 8.9 (s, 1H). M+H = 325	HCl (1:1)
(II-6)	1.35 (s, 12H); 7.25 (t, 1H); from 7.35 to 7.45 (m, 2H); 7.6 (d, 1H); from 8.25 to 8.35 (m, 1H); 8.45 (s, 1H); 8.9 (s, 1H) M+ = 356.	-
(II-7)	1.4 (s, 12H); 6.95 (d, 1H); from 7.55 to 7.85 (m, 7H); 7.95 (d, 1H); 8.05 (m, 2H); 8.55 (s, 1H); 8.75 (s, 1H); 9.05 (s, 1H).	HBr(1:1)
(V-1)	1.35 (m, 12H); 7.4 (d, 1H); 7.5 (d, 1H); 8.1 (s, 1H); 8.85 (s, 1H); M+H = 279; Mp = 115 - 120°C	-
(VII-1)	0.0 (s, 6H); 0.8 (s, 9H); 4.6 (s, 2H); 6.2 (d, 1H); 6.45 (d, 1H); 7.3 (d, 1H); from 7.4 to 7.45 (m, 2H); 8.25 (s, 1H)	-
(VII-2)	0.0 (s, 6H); 0.8 (s, 9H); 4.8 (s, 2H); 7.3 (s, 1H); 7.45 (d, 1H); 7.6 (d, 1H); 7.75 (s, 1H); 7.9 (s, 1H); 8.8 (s, 1H).	-
(VII-3)	(CDCl ₃ , δ in ppm): 0 (s, 6H); 0.85 (s, 9H); 4.65 (s, 2H); 7.1 (m, 1H); 7.45 to 7.55 (m, 3H); 7.65 (dd, 1H); 8.45 (d, 1H); 8.7 (s, 1H). M+H = 374; Mp = 111 - 114°C	-
(VII-4)	0.0 (s, 6H); 0.8 (s, 9H); 4.85 (s, 2H); 7.45 (d, 1H); 7.75 (d, 1H); 8.0 (m, 2H); 8.95 (s, 1H).	-

(X-1)	0.0 (s, 6H); 0.8 (s, 9H); 4.55 (s, 2H); 6.05 (s, 2H); 6.3 (s, 1H); 6.4 (d, 1H); 6.5 (s, 1H); 7.55 (d, 1H); 8.2 (s, 1H). M+H = 305	-
(X-2)	0.0 (s, 6H); 0.8 (s, 9H); 4.85 (s, 2H); 5.85 (s, 2H); 6.4 (d, 1H); 7.2 (s, 1H); 7.4 (s, 1H); 7.55 (d, 1H); 8.15 (s, 1H).	-
(X-3)	0.0 (s, 6H); 0.8 (s, 9H); 4.85 (s, 2H); 5.95 (s, 2H); 6.35 (d, 1H); 7.6 (s, 1H); 7.75 (d, 1H); 8.35 (s, 1H).	-
(X-4)	(CDCl ₃ , δ in ppm): 0 (s, 9H); 1.4 (s, 6H); 4.4 (s, 2H); 6.45 (d, 1H); 7.05 (m, 1H); 7.55 (s, 1H); 7.95 (m, 1H); 8.4 (d, 1H); 8.5 (m, 1H). M+H = 302	-

The following examples describe the preparation of certain compounds in accordance with the invention. These examples are not limiting and merely illustrate the present invention.

- 5 The nomenclature of the compounds was established on the basis of the Autonom software.

Example 1: {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol (compound 1 of the table)

1.1 2-(4-Chlorophenyl)-6-iodoimidazo[1,2-*a*]pyridine

- 10 5.0 g of 2-amino-5-iodopyridine, 5.3 g of 2-bromo-1-(4-chlorophenyl)ethanone and 2.67 g of sodium hydrogen carbonate in 150 ml of n-propanol are placed in a round-bottomed flask. The mixture is heated at 80°C for 40 h and left to cool, and 700 ml of water are added. The precipitate is recovered by filtration, washed with water and dried under reduced pressure. 5.51 g of compound are obtained.

- 15 ¹H NMR (DMSO-d₆, δ in ppm): 7.45 (s, 2H); 7.55 (d, 2H); 8 (d, 2H); 8.35 (s, 1H); 8.95 (s, 1H). M+H = 355.

1.2 5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-carbaldehyde

- 20 300 mg of 2-(4-chlorophenyl)-6-iodoimidazo[1,2-*a*]pyridine, 118 mg of 5-formyl-2-furanboronic acid, 89 mg of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, 280 mg of potassium carbonate, 1.5 ml of ethanol and 1 ml of water are placed in a microwave tube and degassed with argon. The tube is placed in a microwave apparatus and irradiated at 90°C for 30 min. After cooling, the catalyst is removed by filtration and washed

with ethyl acetate. The organic phase is separated and dried and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel chromatography, elution being carried out with a dichloromethane/methanol mixture. 104 mg of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 7.30 (d, 1H); 7.54 (m, 2H); 7.71 (d, 1H); from 7.74 to 7.79 (m, 2H); 8.01 (m, 2H); 8.55 (s, 1H); 9.16 (m, 1H); 9.65 (s, 1H). M+H = 323.

1.3 {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol

122 mg of sodium borohydride are added, in small portions, to 104 mg of 5-[2-(4-chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-carbaldehyde dissolved in 20 ml of methanol. The mixture is subsequently stirred at ambient temperature for 2 hours, and the solvent is then evaporated off under reduced pressure. The residue is taken up between dichloromethane and water. The organic phase is separated, dried over sodium sulphate and concentrated under reduced pressure. 39 mg of compound are obtained.

Mp = 197 - 199°C. ¹H NMR (DMSO-d₆, δ in ppm): 4.5 (d, 2H); 5.3 (t, 1H); 6.5 (m, 1H); 7.95 (m, 1H); 7.55 (m, 2H); from 7.60 to 7.70 (m, 2H); 8 (m, 2H); 8.5 (s, 1H); 8.85 (s, 1H). M+H = 325

Example 2: {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol (compound 11 of the table)

2.1 2-(4-Chlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-*a*]pyridine

2.5 g of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine and 2.65 g of 2-bromo-1-(4-chlorophenyl)ethanone in 76 ml of n-propanol are placed in a round-bottomed flask. 1.33 g of sodium hydrogen carbonate are added thereto. The mixture is heated at 80°C for 16 h. The reaction mixture is left to cool and concentrated under reduced pressure. The residue is taken up between water and ethyl acetate, the organic phase is then separated by settling out and dried over magnesium sulphate, and the solvent is then evaporated off under reduced pressure. 3.75 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 1.35 (s, 12H); 7.35 (d, 1H); from 7.5 to 7.6 (m, 3H); 7.95 (d, 2H); 8.45 (d, 1H); 7.85 (s, 1H). M+H = 355.

2.2 [2-(4-chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]boronic acid hydrochloride (1:1)

3.60 g of 2-(4-chlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-*a*]pyridine are dissolved in 112 ml of acetone and 56 ml of water; 101 ml of

1N hydrochloric acid are added thereto, dropwise and with stirring, and the mixture is stirred at ambient temperature for 24 h. The reaction mixture is then concentrated under reduced pressure. The solid obtained is titrated with diethyl ether and recovered by filtration, and then dried in an oven under reduced pressure at 60°C. 3.12 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): from 7.6 to 7.75 (m, 2H); 7.95 (m, 1H); from 8.05 to 8.15 (m, 2H); 8.2 (m, 1H); 8.9 (s, 1H); 9.1 (s, 1H). M+H = 273.

2.3 {4-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-6-yl]thiazol-2-yl}methanol

28 ml of dimethoxyethane and 14 ml of a 2M solution of sodium carbonate are placed in a round-bottomed flask and the mixture is degassed with argon for 10 min. 768 mg of [2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]boronic acid, 482 mg of (4-bromothiazol-2-yl)methanol and 144 mg of tetrakis(triphenylphosphine)palladium are added. The mixture is left to stir for 16 h at 80°C. The solvent is then evaporated off under reduced pressure. The residue obtained is taken up with ethyl acetate. A precipitate forms, and is recovered by filtration and washed with ethyl acetate. The compound is then purified by silica gel chromatography, elution being carried out with a dichloromethane/methanol mixture. The solid obtained is titrated with diethyl ether and recovered by filtration, and then oven-dried under reduced pressure at 50°C. 350 mg of compound are obtained.

Mp = 190-192°C. ¹H NMR (DMSO-d₆, δ in ppm): 4.85 (s, 2H); 6.2 (t, 1H), from 7.50 to 7.60 (m, 2H); 7.7 (d, 1H); 7.85 (d, 1H); from 7.95 to 8.05 (m, 2H); 8.1 (s, 1H); 8.5 (s, 1H); 9.1 (s, 1H). M+H = 342.

Example 3: [4-[2-quinolin-3-yl]imidazo[1,2-a]pyridin-6-yl]thien-2-yl]methanol hydrochloride (1:2) (compound 16 of the table)

3.1 [4-(Bromothien-2-yl)methoxy]-*tert*-butyldimethylsilane

900 mg of (4-bromothien-2-yl)methanol are placed in a round-bottomed flask and dissolved in 45 ml of tetrahydrofuran. 440 mg of 1H-imidazole are added thereto, followed by 910 mg of *tert*-butyl(chloro)dimethylsilane, and the mixture is left to stir at ambient temperature for 48 hours. The reaction mixture is then hydrolysed with water, and the organic phase, which has been extracted with ethyl acetate, is separated, dried over magnesium sulphate and concentrated under reduced pressure. The residue obtained is purified by silica gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 1.2 g of compound are obtained.

¹H NMR spectrum (CDCl₃, δ in ppm): 0 (s, 6H); 0.85 (s, 9H); 4.7 (s, 2H); 6.7 (s, 1H); 7.0 (s, 1H). M+H = 308.

3.2 Ethyl [2-imino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-pyridin-1-yl]acetate hydrobromide

5 5.0 g of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine in 7.6 ml of ethyl 2-bromoacetate are placed in a round-bottomed flask and the mixture is stirred at ambient temperature for 20 h. A precipitate forms, and is recovered by filtration, washed with diethyl ether and then with ethanol, and oven-dried under reduced pressure. 8.78 g of compound are obtained.

10 ¹H NMR spectrum (DMSO-d₆, δ in ppm): 1.3 (m, 15H); from 4.1 to 4.25 (m, 2H); 5.2 (s, 2H); 7.1 (d, 1H); 8.0 (d, 1H); 8.3 (s, 1H); 9.0 (s, 1H). M+H = 388.

3.3 2-Chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine

8.78 g of ethyl [2-imino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyridin-1-yl]acetate hydrobromide in 20 ml of POCl₃ are placed in a round-bottomed flask. The
15 reaction mixture is heated at 105°C for 16 h, cooled to ambient temperature and concentrated under reduced pressure. The residue is taken up between dichloromethane and water at 0°C, and a 30% aqueous solution of NH₄OH is added until a basic pH is obtained. The organic phase is separated, dried over magnesium sulphate and concentrated under reduced pressure. 4.3 g of compound are obtained.

20 Mp = 115 - 120°C. ¹H NMR spectrum (DMSO-d₆, δ in ppm): 1.35 (m, 12H); 7.4 (d, 1H); 7.5 (d, 1H); 8.1 (s, 1H); 8.85 (s, 1H). M+H = 279.

3.4 6-[5-[(*tert*-Butyldimethylsilanyl)oxymethyl]thien-3-yl]-2-chloroimidazo[1,2-a]pyridine

1.0 g of [(4-bromothien-2-yl)methyloxy]*tert*-butyldimethylsilane in 16 ml of
25 tetrahydrofuran and 4 ml of water are placed in a round-bottomed flask and degassed under a stream of argon for 10 min. 1.0 g of 2-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine, 210 mg of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium and 3.2 g of caesium carbonate are added thereto, and the mixture is heated at 80°C for 16 hours. After cooling, the reaction mixture is
30 concentrated under reduced pressure. The residue obtained is purified by silica gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 450 mg of compound are obtained.

Mp = 100 - 104°C. ¹H NMR spectrum (CDCl₃, δ in ppm): 0 (s, 6H); 0.8 (s, 9H); 4.8 (s, 2H); 7.3 (s, 1H); 7.45 (d, 1H); 7.6 (d, 1H); 7.75 (s, 1H); 7.9 (s, 1H); 8.75 (s, 1H). M+H = 379.

3.5 3-{6-[5-((*tert*-Butyldimethylsilyl)oxymethyl)thien-3-yl]imidazo[1,2-*a*]pyridin-2-yl}quinoline

5 In a reactor, 150 mg of 6-[5-[(*tert*-butyldimethylsilyl)oxymethyl]thien-3-yl]-2-chloroimidazo[1,2-*a*]pyridine are placed in 2 ml of toluene and the mixture is degassed with argon for 10 min. 3 mg of palladium acetate, 11 mg of 2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl, 170 mg of K₃PO₄, 110 mg of 3-quinolineboronic acid and a few drops of ethanol are then added. The reaction mixture is heated at 115°C for 16 h, cooled to
10 ambient temperature and concentrated under reduced pressure. The residue is then purified by silica gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 200 mg of compound are obtained.

M+H = 472.

3.6 [4-(2-Quinolin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl]methanol

15 190 mg of 3-{6-[5-[(*tert*-butyldimethylsilyl)oxymethyl]thien-3-yl]imidazo[1,2-*a*]pyridin-2-yl}quinoline in 4 ml of tetrahydrofuran are placed in a round-bottomed flask, and 210 mg of tetrabutylammonium fluoride are added. After stirring for 48 hours at ambient temperature, the reaction mixture is concentrated under reduced pressure. The residue is then purified by silica gel chromatography, elution being carried out with a
20 dichloromethane/methanol mixture. 100 mg of compound are obtained.

¹H NMR spectrum (DMSO-d₆, δ in ppm): 4.7 (d, 2H); 5.55 (t, 1H); 7.5 (s, 1H); from 7.65 to 7.8 (m, 4H); from 7.9 (s, 1H); 8.05 to 8.15 (m, 2H); 8.65 (s, 1H); 8.9 (s, 1H); 9.0 (s, 1H); 9.55 (1H). M+H = 358.

3.7 [4-[(2-Quinolin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl]methanol

25 hydrochloride (1:2)

100 mg of [4-[(2-quinolin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl]methanol are suspended in dichloromethane and methanol. The solution is passed through a frit and 5.6 ml of a 0.1N solution of hydrochloric acid in isopropanol are added to the filtrate. The reaction mixture is then concentrated under reduced pressure and the residue is then taken
30 up in diethyl ether. The precipitate is recovered by filtration and oven-dried under reduced pressure. 106 mg of compound are obtained.

Mp = 310 - 315°C. ¹H NMR spectrum (DMSO-d₆, δ in ppm): 4.75 (s, 2H); 7.55 (s, 1H); 7.8 (t, 1H); from 7.9 to 8.0 (m, 2H); 8.05 (s, 1H); from 8.17 to 8.25 (m, 3H); 8.9 (s, 1H); 9.28 (s, 1H); 9.32 (s, 1H); 9.67 (s, 1H). M+H = 431.

Example 4: {5-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol
(compound 32 of the table)

4.1 (5-Bromofuran-2-yl)methanol

In a 1 l round-bottomed flask, 10 g (0.052 mol) of 5-bromofuroic acid are dissolved in 350 ml of THF, 5.8 g (0.057 mol) of *N*-methylmorpholine are added, and the mixture is cooled using an ice bath. 7.5 g (0.055 mol) of isobutyl chloroformate in solution in 50 ml of THF are added using a dropping funnel. When the addition is complete, the mixture is left to stir for one hour in the cold, and then the solid formed is removed by filtration through celite. The filtrate is cooled with an ice bath, and then 4.95 g of sodium borohydride and, finally, very slowly, 50 ml of methanol are added. The mixture is left to stir for one hour in the cold and then the solvents are evaporated off under reduced pressure. The residue is taken up between water and diethyl ether, and the organic phase is separated by settling out, washed with water and dried over sodium sulphate. After evaporation of the solvent, 9.1 g of oil are obtained, and used without purification for the subsequent stage.

4.2 [(5-Bromofuran-2-yl)methoxy]-*tert*-butyldimethylsilane

9.1 g (0.051 mol) of the compound obtained in 4.1 are dissolved in 150 ml of THF. 5.2 g (0.077 mol) of imidazole are added thereto, followed by 10 g of chloro-*tert*-butyldimethylsilane, and the mixture is left to stir for 16 hours at ambient temperature. The solvent is then evaporated off under reduced pressure, the residue is taken up between water and diethyl ether, the resulting product is separated by settling out, and the organic phase is washed with water and dried over sodium sulphate. After evaporation of the solvent, the product is purified by chromatography, elution being carried out with a heptane/ethyl acetate mixture. 10.1 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 0.0 (s, 6H); 0.8 (s, 9H); 4.45 (s, 2H); 6.2 (s, 1H); 7.2 (s, 1H)

4.3 6-[5-(*tert*-Butyldimethylsilanyloxymethyl)furan-2-yl]-2-chloroimidazo[1,2-*a*]pyridine

In a 150 ml round-bottomed flask, 68 ml of THF and 12 ml of water are degassed for 15 minutes under argon, and then 4.56 g (15.7 mmol) of the compound obtained in 4.2, 4.36 g (15.7 mmol) of the compound obtained in 3.3, 15.3 g (47 mmol) of caesium carbonate

and 0.38 g of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium are added and the mixture is heated in a thermostated bath at 80°C for 1 h 30. The solvents are then evaporated off under reduced pressure, the residue is taken up between water and diethyl ether, and the resulting product is separated by settling out and dried over sodium sulphate. After
5 evaporation of the solvent, the product is purified by chromatography, elution being carried out with a dichloromethane/methanol mixture, and then recrystallization from cyclohexane. 4.2 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 0,0 (s, 6H); 0.8 (s, 9H); 4.6 (s, 2H); 6.2 (d, 1H); 6.45 (d, 1H); 7.3 (d, 1H); from 7.4 to 7.45 (m, 2H); 8.25 (s, 1H).

10 **4.4 6-[5-(*tert*-Butyldimethylsilanyloxymethyl)furan-2-yl]-2-(1*H*-indol-6-yl)imidazo[1,2-*a*]pyridine**

108 mg (0.3 mmol) of the compound obtained in 4.3 are placed in a tube, and 0.35 mmol of potassium phosphate, 1 ml of n-butanol and 30 mg of indole-6-boronic acid in solution in 2 ml of degassed toluene are added. The tube is flushed with argon and a solution of
15 0.0036 mmol of palladium acetate and of 0.0072 mmol of 2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl in 1 ml of toluene is added thereto. The tube is closed and stirred for 16 h at 110°C. The cooled solution is diluted with 5 ml of ethyl acetate, 100 mg of silica-propanethiol are added thereto, and the mixture is stirred for 4 h at ambient temperature. The solid is separated by filtration and washed with ethyl acetate. The filtrate is evaporated
20 to dryness and used as it is for the next stage.

4.5 {5-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol

The compound obtained in 4.4 is dissolved in 5 ml of THF containing 0.36 mmol of tetrabutylammonium fluoride hydrate. The mixture is stirred for 16 h at ambient temperature, and the solvent is then evaporated off under reduced pressure. The compound
25 is purified by chromatography. 3.9 mg of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 4.45 (m, 2H); 5.3 (m, 1H); 6.45 (m, 2H); 6.9 (s, 1H); 7.4 (m, 1H); 7.55 to 7.65 (m, 4H); 8 (s, 1H); 8.4 (s, 1H); 8.85 (s, 1H); 11.2 (s, 1H). M+H = 330.

Example 5: {4-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol (compound 66 of the table)

5.1 4-Bromo-2-(*tert*-butyldimethylsilanyloxymethyl)thiazole

By carrying out the process as in Example 4.2 and using 5.0 g of (4-bromothiazol-2-yl)methanol dissolved in 255 ml of tetrahydrofuran, 2.28 g of 1*H*-imidazole and 4.66 g of *tert*-butylchlorodimethylsilane, 8.18 g of compound are obtained.

¹H NMR (DMSO-*d*₆, δ in ppm): 0.0 (s, 6H); 0.8 (s, 9H); 4.85 (s, 2H); 7.7 (s, 1H).

5.2 5-[2-(*tert*-Butyl-dimethylsilanyloxymethyl)thiazol-4-yl]pyridin-2-ylamine

8.0 g of the compound obtained in stage 5.1, 6.56 g of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine, 49.7 ml of 2M solution of sodium carbonate and 1.01 g of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium are dissolved in 310 ml of *N,N*-dimethylformamide and placed in a round-bottomed flask under an argon stream. The mixture is heated for 2 h30 at 80°C. After cooling to ambient temperature, 600 ml of ethyl acetate are added to the reaction medium, and the resulting mixture is filtered through celite. The organic phase is then separated, washed three times with a saturated solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue is purified by silica gel chromatography, elution being carried out with a dichloromethane/ethyl acetate mixture. The solid obtained is titrated from diisopropyl ether, recovered by filtration and then oven-dried under reduced pressure. 4.5 g of compound are obtained.

¹H NMR (DMSO-*d*₆, δ in ppm): 0.0 (s, 6H); 0.8 (s, 9H); 4.85 (s, 2H); 5.95 (s, 2H); 6.35 (d, 1H); 7.6 (s, 1H); 7.75 (d, 1H); 8.35 (s, 1H).

5.3 6-[2-(*tert*-Butyldimethylsilanyloxymethyl)thiazol-4-yl]-2-(2-fluorophenyl)imidazo[1,2-*a*]pyridine

58.8 mg (0.7 mmol) of sodium bicarbonate are weighed into a microwave tube. 57 mg (0.25 mmol) of the compound obtained in 5.2, in solution in 2 ml of propan-1-ol, are added thereto, followed by 92 mg (0.375 mmol) of 2-bromo-1-(2-fluorophenyl)ethanone in solution in 1 ml of propan-1-ol. The tube is sealed and then stirred for 16 h at 80°C. The reaction mixture is cooled to ambient temperature, 200 mg of propanethiol supported on silica (Biotage Si-Thiol) are added thereto and the mixture is stirred for 6 h at ambient temperature and then filtered. The residue is washed with twice 2 ml of propan-1-ol and then the filtrate is evaporated. The crude compound is used as it is in the next stage.

5.4 {4-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol

The crude compound obtained in 5.3 is dissolved in 5 ml of THF containing 0.5 mmol of tetrabutylammonium fluoride hydrate. The mixture is stirred for 16 h at ambient temperature, and the solvent is then evaporated off under reduced pressure. The compound is purified by chromatography. 4.1 mg of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 4.82 (s, 2H); 6.19 (m, 1H); 7.31 (m, 2H); 7.38 (m, 1H); 7.67 (d, 1H); 7.84 (d, 1H); 8.08 (s, 1H); 8.38 (t, 1H); 8.45 (d, 1H); 9.22 (s, 1H).

Example 6: 2-{2-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol (compound 152 of the table)**6.1 *N*-Methoxy-*N*-methylindole-6-carboxamide**

In a round-bottomed flask, 5.0 g of indole-6-carboxylic acid, 3.3 g of *N,O*-dimethylhydroxylamine hydrochloride, 11.9 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 10 ml of pyridine are placed in 150 ml of tetrahydrofuran. The mixture is stirred at ambient temperature for 40 h. The mixture is concentrated, and the residue is taken up in 150 ml of ethyl acetate and 50 ml of water. The organic phase is washed with 50 ml of a 1N solution of sodium hydroxide and 50 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 6.8 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 3.3 (s, 3H); 3.5 (s, 3H); 6.45 (m, 1H); 7.25 (t, 1H); 7.4 (dd, 1H); 7.55 (d, 1H); 7.75 (s, 1H); 8.8 (s, 1H). M+H = 205.

6.2 *N*-Methoxy-*N*-methyl-1-(phenylsulphonyl)indole-6-carboxamide

In a round-bottomed flask, 6.8 g of compound obtained in 6.1 are placed in 100 ml of *N,N*-dimethylformamide at 0°C. 1.45 g of NaH are added portionwise, followed by 6.52 g of benzenesulphonyl chloride. The mixture is stirred at ambient temperature for 40 h. 150 ml of water are added and the mixture is then extracted with 60 ml of ethyl acetate. The organic phase is washed with 50 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. The residue is purified by silica gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 9.5 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 3.4 (s, 3H); 3.55 (s, 3H); 6.7 (d, 1H); 7.45 to 7.6 (m, 5H); 7.7 (d, 1H); 7.95 (m, 2H); 8.4 (s, 1H). M+H = 345.

6.3 6-acetyl-1-(phenylsulphonyl)indole

In a round-bottomed flask, 9.2 g of compound obtained in 6.2 are placed in 250 ml of tetrahydrofuran at 0°C and under argon. 27 ml of methylmagnesium bromide (3M in diethyl ether) are added dropwise. The mixture is stirred for one hour at 0°C and 20 h at ambient temperature. The mixture is cooled to 0°C and 150 ml of water and 50 ml of a saturated solution of ammonium chloride are added. The mixture is extracted with 60 ml of ethyl acetate. The organic phase is washed with 40 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 7.3 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 2.7 (s, 3H); 6.75 (d, 1H); 7.45 to 7.65 (m, 4H); 7.8 (d, 1H); 7.95 (m, 3H); 8.65 (s, 1H). M+H = 300; Mp = 160 -163°C.

6.4 2-Bromo-1-[1-(phenylsulphonyl)indol-6-yl]ethanone

In a round-bottomed flask, 3 g of copper bromide are placed in 120 ml of ethyl acetate and the mixture is refluxed. 2 g of 6-acetyl-1-(phenylsulphonyl)indole are added. The mixture is stirred for 4 hours at reflux. The mixture is filtered through paper and then the filtrate is poured into 150 ml of a 20% solution of sodium thiosulphate. The mixture is extracted with 60 ml of ethyl acetate. The organic phase is washed with 40 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 2.6 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 4.45 (s, 2H); 6.65 (d, 1H); 7.35 to 7.55 (m, 4H); 7.7 (d, 1H); 7.9 (m, 3H); 8.6 (s, 1H). M+H = 378

6.5 2-(1-Phenylsulphonyl-1*H*-indol-6-yl)-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)imidazo[1,2-*a*]pyridine hydrobromide

1.6 g of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine and 2.7 g of 2-bromo-1-[1-(phenylsulphonyl)indol-6-yl]ethanone are placed in 70 ml of ethanol and the mixture is refluxed for 20 h. A precipitate forms and is recovered by filtration, washed with diethyl ether and oven-dried under reduced pressure. 2.3 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 1.4 (s, 12H); 6.95 (d, 1H); from 7.55 to 7.85 (m, 7H); 7.95 (d, 1H); 8.05 (m, 2H); 8.55 (s, 1H); 8.75 (s, 1H); 9.05 (s, 1H).

6.6 2-Bromo-*N*-methoxy-*N*-methylisonicotinamide

In a round-bottomed flask, 2.0 g of 2-bromoisonicotinic acid, 1.1 g of *N,O*-dimethylhydroxylamine hydrochloride, 3.8 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 3.2 ml of pyridine are placed in 50 ml of tetrahydrofuran. The mixture is stirred at ambient temperature for 40 h. The mixture is concentrated, and the residue is taken up in 50 ml of ethyl acetate and 50 ml of water. The organic phase is washed with 50 ml of a 1N solution of sodium hydroxide and 50 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 2.0 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 3.3 (s, 3H); 3.5 (s, 3H); 7.4 (d, 1H); 7.65 (s, 1H); 8.4 (d, 1H). M+H = 245.

6.7 2-Bromo-4-acetylpyridine

In a round-bottomed flask, 2.0 g of compound obtained in 6.6 are placed in 80 ml of tetrahydrofuran at 0°C and under argon. 8 ml of methylmagnesium bromide (3M in ethyl ether) are added dropwise. The mixture is stirred for one hour at 0°C and 20 h at ambient temperature. It is cooled to 0°C and 80 ml of water and 40 ml of a saturated solution of ammonium chloride are added. The mixture is extracted with 40 ml of ethyl acetate. The organic phase is washed with 40 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 1.6 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 2.55 (s, 3H); 7.6 (d, 1H); 7.85 (s, 1H); 8.5 (d, 1H). M+H = 200.

6.8 2-(2-Bromopyridin-4-yl)propan-2-ol

In a round-bottomed flask, 1.1 g of compound obtained in 6.7 are placed in 60 ml of tetrahydrofuran at 0°C and under argon. 13 ml of methylmagnesium bromide (3M in ethyl ether) are added dropwise. The mixture is stirred for one hour at 0°C and 20 h at ambient temperature. It is cooled to 0°C and 60 ml of water and 30 ml of a saturated solution of ammonium chloride are added. The mixture is extracted with 40 ml of ethyl acetate. The organic phase is washed with 40 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 1.5 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 1.55 (s, 6H); 7.35 (d, 1H); 7.6 (s, 1H); 8.3 (d, 1H).

6.9 2-Bromo-4-[1-methyl-1-(trimethylsilyloxy)ethyl]pyridine

In a round-bottomed flask, 1.5 g of 2-(2-bromo-pyridin-4-yl)propan-2-ol obtained in 6.8 are placed in 35 ml of dichloromethane at 0°C. 2.4 ml of triethylamine and 1.9 ml of trimethylsilane chloride are added. The mixture is stirred for one hour at 0°C and 20 h at ambient temperature. 20 ml of water are added and the mixture is extracted with 20 ml of dichloromethane. The organic phase is washed with 20 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. The residue is purified by silica gel chromatography, elution being carried out with a dichloromethane/methanol mixture. 0.7 g of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 0 (s, 9H); 1.4 (s, 6H); 7.1 (d, 1H); 7.35 (s, 1H); 8.1 (d, 1H).

6.10 2-(1-Phenylsulphonyl-1*H*-indol-6-yl)-6-[4-[1-methyl-1-(trimethylsilyloxy)ethyl]pyridin-2-yl]imidazo[1,2-*a*]pyridine

0.2 g of compound obtained in 6.9 in 4 ml of tetrahydrofuran and 1 ml of water are placed in a round-bottomed flask and degassed under an argon stream for 10 min. 0.4 g of hydrobromide of the compound obtained in 6.5, 45 mg of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium and 0.9 g of caesium carbonate are added thereto and the mixture is heated at 80°C for 4 hours. After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by silica gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 200 mg of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 0 (s, 9H); 1.4 (s, 6H); 6.45 (d, 1H); 7.1 (m, 1H); 7.2 to 7.4 (m, 5H); 7.55 (m, 3H); 7.7 to 7.85 (m, 4H); 8.35 (s, 1H); 8.4 (d, 1H); 8.75 (s, 1H). M+H = 581.

6.11 2-{2-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol

0.2 g of the compound obtained in 6.10 in 4 ml of ethanol are placed in a round-bottomed flask and 1.7 ml of a 1N solution of sodium hydroxide are added. The mixture is stirred at 80°C for 20 h. The reaction mixture is concentrated under reduced pressure and the residue obtained is purified by silica gel chromatography, elution being carried out with a dichloromethane/methanol mixture. 64 mg of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 1.55 (s, 6H); 5.35 (s, 1H); 6.45 (s, 1H); 7.4 (t, 1H); 7.45 (d, 1H); 7.65 (m, 2H); 7.7 (d, 1H); 8.0 (d, 1H); 8.1 (m, 2H); 8.45 (s, 1H); 8.6 (d, 1H); 9.3 (s, 1H); 11.2 (s, 1H).

Example 7: 2-{2-[2-(1*H*-Indazol-3-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol (compound 153 of the table)

7.1 4-[1-Methyl-1-(trimethylsilyloxy)ethyl][2,3']bipyridinyl-6'-ylamine

0.5 g of the compound obtained in 6.9, 8 ml of tetrahydrofuran and 2 ml of water are placed
5 in a round-bottomed flask and degassed under an argon stream for 10 min. 10.4 g of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylamine, 110 mg of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium and 1.1 g of caesium carbonate are added thereto and the mixture is heated at 80°C for 4 hours. After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by silica
10 gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 240 mg of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 0 (s, 9H); 1.4 (s, 6H); 4.4 (s, 2H); 6.45 (d, 1H); 7.05 (m, 1H); 7.55 (s, 1H); 7.95 (m, 1H); 8.4 (d, 1H); 8.5 (m, 1H). M+H = 302.

7.2 *N*-Methoxy-*N*-methyl-1*H*-indazole-3-carboxamide

15 In a round-bottomed flask, 4.0 g of 1*H*-indazole-3-carboxylic acid, 2.6 g of *N,O*-dimethylhydroxylamine hydrochloride, 9.4 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 8.4 ml of pyridine are placed in 120 ml of tetrahydrofuran. The mixture is stirred at ambient temperature for 20 h. The mixture is concentrated and the residue is taken up in water. The yellow precipitate obtained is washed with water and then
20 dried under reduced pressure. 3.5 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 3.5 (s, 3H); 3.8 (s, 3H); 7.25 (m, 1H); 7.45 (m, 1H); 7.65 (d, 1H); 8.05 (d, 1H); 13.65 (s, 1H). M+H = 206.

7.3 1-(1*H*-Indazol-3-yl)ethanone

In a round-bottomed flask, 2.4 g of *N*-methoxy-*N*-methyl-1*H*-indazole-3-carboxamide are
25 placed in 140 ml of tetrahydrofuran at 0°C and under argon. 19 ml of methylmagnesium bromide (3M in ethyl ether) are added dropwise. The mixture is stirred for one hour at 0°C and 20 h at ambient temperature. It is cooled to 0°C and 80 ml of water and 40 ml of a saturated solution of ammonium chloride are added. The mixture is extracted with 40 ml of ethyl acetate. The organic phase is washed with 40 ml of a saturated solution of sodium
30 chloride, dried over magnesium sulphate and then concentrated under reduced pressure. The residue is purified by silica gel chromatography, elution being carried out with a heptane/ethyl acetate mixture. 1.6 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 2.65 (s, 3H); 7.35 (m, 1H); 7.55 (m, 1H); 7.7 (d, 1H); 8.2 (d, 1H); 13.9 (s, 1H). M+H = 161.

7.4 2-Bromo-1-(1*H*-indazol-3-yl)ethanone

In a round-bottomed flask, 4.5 g of copper bromide are placed in 180 ml of ethyl acetate and the mixture is refluxed. 1.6 of 1-(1*H*-indazol-3-yl)ethanone are added. The mixture is stirred for 4 hours at reflux. The resulting mixture is filtered through paper and the filtrate is poured into 150 ml of a 20% solution of sodium thiosulphate. The mixture is extracted with 60 ml of ethyl acetate. The organic phase is washed with 40 ml of a saturated solution of sodium chloride, dried over magnesium sulphate and then concentrated under reduced pressure. 2.4 g of compound are obtained.

¹H NMR (DMSO-d₆, δ in ppm): 4.95 (s, 2H); from 7.35 to 7.55 (m, 2H); 7.75 (d, 1H); 8.2 (d, 1H); 14.1 (s, 1H). M+H = 239.

7.5 3-(6-{4-[1-Methyl-1-(trimethylsilyloxy)ethyl]pyridin-2-yl}imidazo[1,2-*a*]pyridin-2-yl)-1*H*-indazole

In a 50 ml round-bottomed flask, 140 mg of the compound obtained in 7.1 and 110 mg of the compound obtained in 7.4 are introduced into 4 ml of ethanol. 40 mg of sodium bicarbonate are added and the mixture is heated at 80°C for 4 h. The solvent is evaporated off under reduced pressure and the residue is purified by chromatography, elution being carried out with a dichloromethane/methanol mixture. 137 mg of compound are obtained.

¹H NMR (CDCl₃, δ in ppm): 0 (s, 9H); 1.45 (s, 6H); 7.15 (m, 2H); 7.2 to 7.35 (m, 2H); 7.6 (m, 3H); 8.1 (s, 1H); 8.35 (d, 1H); 8.45 (d, 1H); 9.85 (s, 1H); 10.2 (s, 1H). M+H = 370.

7.6 2-{2-[2-(1*H*-Indazol-3-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol

130 mg of the compound obtained in 7.5 are dissolved in 2 ml of THF, 90 mg of tetrabutylammonium fluoride hydrate are added thereto and the mixture is stirred for 2 hours at ambient temperature. The solvent is then evaporated off under reduced pressure and the residue is purified by chromatography, elution being carried out with a dichloromethane/methanol mixture. 99 mg of compound are obtained.


¹H NMR (DMSO-d₆, δ in ppm): 1.5 (s, 6H); 5.35 (s, 1H); 7.25 (t, 1H); 7.4 (t, 1H); 7.45 (d, 1H); 7.6 (d, 1H); 7.75 (d, 1H); 8.05 (m, 2H); 8.5 (d, 1H); 8.55 (s, 1H); 8.65 (d, 1H); 9.4 (s, 1H); 13.15 (s, 1H); Mp = 255-259°C.

The tables which follow illustrate the chemical structures of general formula (I) (Table 2) and the physicochemical characteristics (Table 3) of some examples of compounds according to the invention.

In these tables:






















- 5 - "Ph" means phenyl;
- "Cl" means chlorine;
- "F" means fluorine;
- "Br" means bromine;
- "Me" means methyl;
- 10 - "MeO" means methoxy;
- "(F₂CH)O" means difluoromethoxy;
- the "Mp" column gives the melting points of the products in degrees Celsius (°C) or, when the products have been isolated in the form of an amorphous solid or of an oil, they are characterized by their mass [M+H];
- 15 - in the "salt/base" column, "-" represents a compound in free base form, whereas "HCl" represents a compound in hydrochloride form, and the ratio between parentheses is the (acid:base) ratio.



















Table 2















































20

























Ex	R ₁	R		salt
1	4-Cl-Ph	H		-
2	4-Cl-Ph	H		-






















Ex	R ₁	R		salt
3	4-Cl-Ph	H		-
4	4-Cl-Ph	H		-
5	4-Cl-Ph	H		-
6	4-Cl-Ph	H		-
7	4-Cl-Ph	H		-
8	4-Cl-Ph	H		-
9	4-Cl-Ph	H		-
10	4-Cl-Ph	H		-
11	4-Cl-Ph	H		-
12		H		HCl (1:1)
13		H		HCl (2:1)
14	4-Me-Ph	H		-
15		H		HCl (3:2)
16		H		HCl (2:1)
17		H		HCl (1:1)























Ex	R ₁	R		salt
18		H		HCl (1:1)
19	Ph	H		HCl (1:1)
20		H		HCl (1:1)
21	3-MeO-Ph	H		HCl (1:1)
22		H		HCl (1:1)
23	Ph	H		-
24	4-Me-Ph	H		HCl (1:1)
25	Ph	H		-
26	3-OMe-Ph	H		-
27	2,4-diF-Ph	H		-
28	4-Cl-Ph	H		-
29	4-Cl-Ph	H		-
30	4-(CH ₂ OH)-Ph	H		-
31	4-(CONMe ₂)-Ph	H		-

























Ex	R ₁	R		salt
32		H		-
33		H		-
34		H		-
35	4-(N-morpholino)-Ph	H		-
36		H		-
37		H		-
38	4-(Me ₂ NCO)-Ph	H		-
39		H		-
40		H		-
41		H		-
42		H		-
























Ex	R ₁	R		salt
43	4-(Me ₂ NCH ₂)-Ph	H		-
44		H		-
45	3-NH ₂ -Ph	H		-
46		H		-
47	-Ph	3-Me		-
48		3-Me		-
49	3-Cl-Ph	3-Me		-
50	4-Pyrrolidino-Ph	H		-
51	3-Cyano-Ph	H		-
52		H		-
53		H		-
54		H		-
55	4-NO ₂ -Ph	H		-
56		H		-
57	4-SMe-Ph	H		-
























Ex	R ₁	R		salt
58		H		-
59	4-MeSO ₂ -Ph	H		-
60		H		-
61		H		-
62	Ph	3-Me		-
63		3-Me		-
64	4-OMe-Ph	3-Me		-
65	4-Pyrrolidino-Ph	H		-
66	2-F-Ph	H		-
67	4-MeSO ₂ -Ph	H		-
68		H		-
69		H		-
70		H		-
71		H		-
72	4-Pyrrolidino-Ph	H		-





















Ex	R ₁	R		salt
73	4-Cl-Ph	H		-
74	4-Cl-Ph	H		-
75	4-OMe-Ph	3-Me		-
76	4-CF ₃ -Ph	H		-
77	4-OMe-Ph	H		-
78	4-F-Ph	H		-
79	3,4-diF-Ph	H		-
80		H		-
81		H		-
82	2-F-Ph	H		-
83	3-Br-Ph	H		-
84	3-Me-4-Cl-Ph	H		-
85	4-MeSO ₂ -Ph	H		-
86		H		-
87		H		-
88		H		-

Ex	R ₁	R		salt
89		H		-
90		H		-
91		H		-
92	4-SMe-Ph	H		-
93	4-Cl-Ph	3-Me		-
94		3-Me		-
95	3-Cl-Ph	3-Me		-
96	2,4-diF-Ph	3-Me		-
97	4-F-Ph	H		-
98	3,4-diF-Ph	H		-
99	3-Cyano-Ph	H		-
100	2-F-Ph	H		-
101	3-Br	H		-
102		H		-
103		H		-

Ex	R ₁	R		salt
104		H		-
105		H		-
106		H		-
107		H		-
108		H		-
109		H		-
110	4-Cl-Ph	3-Me		-
111	3-Cl-Ph	3-Me		-
112	4-CF ₃ -Ph	H		-
113	4-F-Ph	H		-
114	3,4-diF-Ph	H		-
115		H		-
116		H		-
117		H		-

Ex	R ₁	R		salt
118	3-Br-Ph	H		-
119	4-Cl-3-Me-Ph	H		-
120		H		-
121		H		-
122		H		-
123		H		-
124		H		-
125	3-(CH ₂ OH)-Ph	H		-
126		H		-
127		H		-
128		H		-
129		H		-
130	4-(CH ₂ OH)-Ph	H		-

Ex	R ₁	R		salt
131	3-(CH ₂ OH)-Ph	H		-
132		H		-
133		H		-
134		H		-
135		H		-
136		H		-
137		H		-
138		H		-
139	4-(CONHMe)-Ph	H		-
140		H		-
141		H		-
142		H		-

Ex	R ₁	R		salt
143	4-(MeCONH)-Ph	H		-
144	4-(N-Morpholino)-Ph	H		-
145		H		-
146		H		-
147	3-(Me ₂ NSO ₂)-Ph	H		-
148		H		-
149		H		-
150		H		-
151		H		-
152		H		-
153		H		-







Ex	R ₁	R		salt
154		H		-
155		H		-
156	4-Cl-Ph	H		-

Table 3

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
1	197-199	4.5 (d, 2H); 5.3 (t, 1H); 6.5 (m, 1H); 7.95 (m, 1H); 7.55 (m, 2H); from 7.60 to 7.70 (m, 2H); 8 (m, 2H); 8.5 (s, 1H); 8.85 (s, 1H).
2	190-192°C	4.7 (d, 2H); 5.55 (t, 1H); 7.45 (s, 1H); 7.55 (d, 2H); from 7.60 to 7.70 (m, 2H); 7.85 (s, 1H); 8.05 (d, 2H); 8.4 (s, 1H); 8.95 (s, 1H).
3	227-228°C	4.65 (d, 2H); 5.55 (t, 1H); 7.0 (d, 1H); 7.40 (d, 1H); from 7.50 to 7.70 (m, 4H); 8.0 (d, 2H); 8.45 (s, 1H); 8.85 (s, 1H).
4	207.7-208.4	4.65 (d, 2H); 5.5 (t, 1H); 7.35 (d, 1H); 7.55 (d, 2H); 7.70 (d, 1H); 7.95 (s, 1H); from 8.0 to 8.10 (m, 3H); 8.55 (s, 1H); 8.65 (d, 1H); 9.35 (s, 1H).
5	238.4-239.5	4.65 (d, 2H); 5.4 (t, 1H); 7.55 (d, 2H); from 7.65 to 7.75 (m, 2H); from 8.0 to 8.1 (m, 3H); 8.55 (s, 1H); 8.6 (s, 1H); 8.9 (s, 1H); 9.0 (s, 1H).
6	194.7-195.2	4.4 (d, 2H); 5.3 (t, 1H); 6.8 (s, 1H); from 7.45 to 7.65 (m, 4H); 8.0 (d, 2H); 8.15 (s, 1H); 8.35 (s, 1H); 8.75 (s, 1H).
7	197.4-198.2	4.7 (d, 2H); 5.5 (t, 1H); 7.5 (d, 1H); 7.55 (d, 2H); 7.7 (d, 1H); 7.9 (d, 1H); 7.95 (t, 1H); from 8.0 to 8.10 (m, 3H); 8.6 (s, 1H); 9.3 (s, 1H).
8	211.3-211.9	4.5 (d, 2H); 5.2 (t, 1H); 7.35 (s, 1H); 7.5 (s, 1H); 7.55 (d, 2H); 7.6 (d, 1H); 7.65 (d, 1H); 8.0 (d, 2H); 8.45 (s, 1H); 8.9 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
9	229-231	4.75 (d, 2H); 5.65 (t, 1H); 7.52 (2d, 2H); from 7.7 to 7.8 (m, 3H); 8.0 (d, 2H); 8.52 (s, 1H); 9.22 (s, 1H).
10	193-194	4.65 (d, 2H); 5.4 (t, 1H); 7.5 (m, 3H); 7.7 (m, 2H); 8.0 (d, 2H); 8.55 (s, 1H); 9.3 (s, 1H).
11	190-192	4.85 (s, 2H); 6.2 (t, 1H); from 7.50 to 7.60 (m, 2H); 7.7 (d, 1H); 7.85 (d, 1H); from 7.95 to 8.05 (m, 2H); 8.1 (s, 1H); 8.5 (s, 1H); 9.1 (s, 1H).
12	268-273	4.7 (s, 2H); 7.2 (s, 1H); 7.5 (s, 1H); from 7.9 to 8.1 (m, 3H); from 8.5 to 8.6 (m, 3H); 8.7 (s, 1H); 9.65 (s, 1H).
13	310-315	4.55 (s, 2H); 6.55 (s, 1H); 7.15 (s, 1H); 7.85 (m, 1H); 7.95 (m, 2H); 8.1 (m, 1H); 8.2 (m, 2H); 8.95 (s, 1H); 9.15 (s, 1H); 9.25 (s, 1H); 9.62 (s, 1H).
14	197.5-198	2.35 (s, 3H); 4.7 (d, 2H); 5.55 (t, 1H); 7.25 (d, 2H); 7.45 (s, 1H); 7.6 (m, 2H); 7.8 (s, 1H); 7.87 (d, 2H); 8.3 (s, 1H); 8.9 (s, 1H).
15	255-260	4.73 (s, 2H); 7.5 (d, 1H); 7.8 (t, 1H); 7.93 (t, 1H); 8.0 (d, 1H); 8.1 (s, 1H); 8.2 (m, 2H); 8.4 (d, 1H); 8.72 (d, 1H); 9.0 (s, 1H); 9.2 (s, 1H); 9.58 (s, 1H); 9.63 (s, 1H).
16	310-315	4.75 (s, 2H); 7.55 (s, 1H); 7.8 (t, 1H); from 7.9 to 8.0 (m, 2H); 8.05 (s, 1H); from 8.17 to 8.25 (m, 3H); 8.9 (s, 1H); 9.328 (s, 1H); 9.32 (s, 1H); 9.67 (s, 1H).
17	390-395	4.75 (s, 2H); 6.6 (s, 1H); 7.5 (m, 2H); 7.6 (d, 1H); 7.75 (d, 1H); 7.95 (d, 1H); 8.05 (s, 1H); 8.25 (m, 2H); 8.6 (s, 1H); 9.25 (s, 1H); 11.45 (s, 1H).
18	390-395	4.55 (s, 2H); 6.55 (s, 1H); 6.6 (s, 1H); 7.15 (m, 1H); 7.5 (m, 1H); 7.6 (d, 1H); 7.7 (d, 1H); 7.95 (d, 1H); 8.15 (d, 1H); 8.25 (s, 1H); 8.65 (s, 1H); 9.1 (s, 1H); 11.45 (s, 1H).
19	267	4.75 (s, 2H); from 7.5 to 7.6 (m, 2H); 7.65 (m, 2H); 8.0 (m, 2H); 8.1 (d, 2H); 8.3 (d, 1H); 8.7 (s, 1H); 9.3 (s, 1H).
20	405-410	4.75 (s, 2H); 6.65 (m, 1H); 7.55 (s, 1H); 7.65 (m, 1H); 7.95 (d, 1H); 8.05 (s, 1H); 8.25 (d, 1H); 8.6 (s, 1H); 8.7 (s, 1H); 8.9 (s, 1H); 9.25 (s, 1H); 12.05 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
21	305	3.9 (s, 3H); 4.7 (s, 2H); 7.1 (d, 1H); 7.55 (m, 2H); 7.65 (d, 1H); 7.7 (s, 1H); 7.95 (d, 1H); 8.0 (s, 1H); 8.25 (d, 1H); 8.7 (s, 1H); 9.2 (s, 1H).
22	305-310	4.7 (s, 2H); 6.65 (m, 1H); 7.5 (m, 1H); 7.65 (m, 1H); 8.05 (s, 1H); 8.1 (s, 1H); 8.6 (d, 1H); 8.65 (s, 1H); 8.7 (d, 1H); 8.85 (s, 1H); 8.9 (s, 1H); 9.65 (s, 1H); 12.1 (s, 1H).
23	225-226	4.65 (d, 2H); 5.55 (t, 1H); 7.35 (m, 2H); 7.5 (m, 2H); 7.7 (d, 1H); from 7.95 to 8.05 (m, 4H); 8.5 (s, 1H); 8.65 (d, 1H); 9.35 (s, 1H).
24	248-254	2.4 (s, 3H); 4.5 (s, 2H); 6.55 (d, 1H); 7.15 (d, 1H); 7.45 (d, 2H); from 7.85 to 8.0 (m, 3H); 8.15 (d, 1H); 8.7 (s, 1H); 9.1 (s, 1H).
25	202-204	4.5 (s, 2H); 5.3 (m, 1H); 6.45 (d, 1H); 6.95 (d, 1H); 7.35 (m, 1H); 7.5 (m, 2H); 7.65 (m, 2H); 7.95 (d, 2H); 8.5 (s, 1H); 8.9 (s, 1H).
26	172-174	3.85 (s, 3H); 4.5 (s, 2H); 5.3 (s, 1H); 6.45 (s, 1H); 6.95 (m, 2H); 7.4 (m, 1H); 7.55 (m, 2H); 7.65 (m, 2H); 8.5 (s, 1H); 8.85 (s, 1H).
27	207-208	4.5 (d, 2H); 5.3 (t, 1H); 6.5 (s, 1H); 6.95 (s, 1H); 7.25 (m, 1H); 7.4 (m, 1H); 7.65 (m, 2H); 8.3 (m, 1H); 8.45 (s, 1H); 8.95 (s, 1H).
28	174-176	4.45 (d, 2H); 5.05 (t, 1H); 7.00 (s, 1H); from 7.55 (d, 2H); from 7.6 to 7.7 (m, 3H); 8.0 (d, 2H); 8.45 (s, 1H); 8.85 (s, 1H).
29	176-178	3.3 (s, 3H); 4.3 (s, 2H); 7.0 (s, 1H); 7.5 (d, 2H); from 7.65 to 7.8 (m, 3H); 8.0 (d, 2H); 8.45 (s, 1H); 8.9 (s, 1H).
30	[321]	4.47 (d, 2H); 4.55 (d, 2H); 5.2 (t, 1H); 5.31 (t, 1H); 6.42 (s, 1H); 6.91 (s, 1H); 7.4 (m, 2H); 7.6 (m, 2H); 7.91 (m, 2H); 8.41 (s, 1H); 8.82 (s, 1H).
31	[362]	3 (m, 6H); 4.49 (m, 2H); 5.3 (m, 1H); 6.42 (s, 1H); 6.92 (s, 1H); 7.5 (m, 2H); 7.62 (m, 2H); 8 (m, 2H); 8.51 (s, 1H); 8.75 (s, 1H).
32	[330]	4.45 (m, 2H); 5.3 (m, 1H); 6.45 (m, 2H); 6.9 (s, 1H); 7.4 (m, 1H); 7.55 to 7.65 (m, 4H); 8 (s, 1H); 8.4 (s, 1H); 8.85 (s, 1H); 11.2 (s, 1H).
33	[322]	4.08 (s, 3H); 4.49 (m, 2H); 5.3 (m, 1H); 6.42 (d, 1H); 6.9 (d, 1H); 7.12 (m, 1H); 7.6 (m, 2H); 8.26 (m, 1H); 8.55 (m, 2H); 8.95 (s, 1H).
34	[342]	4.5 (d, 2H); 5.32 (t, 1H); 6.49 (s, 1H); 6.94 (s, 1H); 7.6 (m, 1H); 7.68 (d, 1H); 7.76 (d, 1H); 7.83 (m, 1H); 7.95 (d, 1H); 8.07 (d, 1H); 8.5 (s, 1H); 8.92 (m, 2H); 9.31 (d, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
35	[376]	3.15 (m, 4H); 3.75 (m, 4H); 4.49 (m, 2H); 5.3 (m, 1H); 6.42 (d, 1H); 6.9 (d, 1H); 7 (m, 2H); 7.56 (m, 2H); 7.8 (m, 2H); 8.3 (s, 1H); 9.89 (s, 1H).
36	[342]	4.5 (d, 2H); 5.32 (t, 1H); 6.49 (s, 1H); 6.99 (s, 1H); 7.69 (m, 1H); 7.73 (m, 2H); 8.18 (m, 2H); 8.51 (s, 1H); 8.58 (d, 1H); 8.29 (d, 1H); 8.94 (s, 1H); 9.4 (s, 1H).
37	[388]	1.3 (d, 3H); 1.7 (m, 4H); 2.3 (m, 2H); 2.5 (m, 2H); 3.2 (q, 1H); 4.5 (d, 2H); 5.3 (t, 1H); 6.45 (d, 1H); 6.9 (d, 1H); 7.4 (m, 2H); 7.6 (m, 2H); 7.9 (m, 2H); 8.4 (s, 1H); 8.8 (s, 1H)
38	[378]	3 (m, 6H); 4.7 (m, 2H); 5.59 (m, 1H); 7.42 (m, 1H); 7.5 (m, 2H); 7.65 (m, 2H); 7.81 (s, 1H); 8.01 (m, 2H); 8.41 (s, 1H); 8.91 (s, 1H).
39	[338]	4.08 (s, 3H); 4.69 (m, 2H); 5.58 (m, 1H); 7.15 (m, 1H); 7.4 (s, 1H); 7.62 (m, 2H); 7.8 (s, 1H); 8.16 (m, 1H); 8.41 (s, 1H); 8.59 (d, 1H); 9.01 (s, 1H).
40	[358]	4.7 (d, 2H); 5.59 (t, 1H); 7.44 (s, 1H); 7.75 (m, 3H); 7.85 (s, 1H); 8.15 (m, 2H); 8.4 (s, 1H); 8.58 (d, 1H); 8.9 (d, 1H); 9 (s, 1H); 9.39 (s, 1H).
41	[392]	1.11 (d, 6H); 2.51 (m, 1H); 4.68 (m, 2H); 5.57 (m, 1H); 7.33 (m, 1H); 7.41 (s, 1H); 7.6 (m, 4H); 7.8 (s, 1H); 8.29 (s, 2H); 8.9 (s, 1H); 9.9 (s, 1H).
42	[404]	1.3 (d, 3H); 1.7 (m, 4H); 2.3 (m, 2H); 2.5 (m, 2H); 3.2 (q, 1H); 4.7 (d, 2H); 5.55 (t, 1H); 7.4 (m, 3H); 7.6 (m, 2H); 7.8 (s, 1H); 7.9 (d, 2H); 8.3 (s, 1H); 8.9 (s, 1H)
43	[364]	2.18 (s, 6H); 3.4 (s, 2H); 4.68 (d, 2H); 5.58 (t, 1H); 7.32 (d, 2H); 7.41 (s, 1H); 7.6 (m, 2H); 7.71 (s, 1H); 7.92 (m, 2H); 8.31 (s, 1H); 8.9 (s, 1H).
44	[396]	2.9 (s, 3H); 3.2 (s, 3H); 4.68 (m, 2H); 5.56 (m, 1H); 7.43 (m, 2H); 7.64 (m, 2H); 7.83 (s, 1H); 7.89 (m, 2H); 8.47 (s, 1H); 8.91 (s, 1H).
45	[322]	4.68 (m, 2H); 5.11 (m, 2H); 5.55 (m, 1H); 6.5 (d, 1H); 7.05 (m, 2H); 7.22 (s, 1H); 7.41 (s, 1H); 7.59 (m, 2H); 7.8 (s, 1H); 8.18 (s, 1H); 8.9 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
46	[407]	1.42 (s, 9H); 4.69 (m, 2H); 5.08 (m, 1H); 7.45 (s, 1H); 7.68 (m, 2H); 7.85 (s, 1H); 8.17 (s, 1H); 8.52 (s, 1H); 8.61 (m, 1H); 8.86 (s, 1H); 8.95 (s, 1H); 9.27 (s, 1H).
47	[305]	2.71 (s, 3H); 4.5 (d, 2H); 5.32 (t, 1H); 6.44 (d, 1H); 6.99 (d, 1H); 7.35 (m, 1H); 7.48 (m, 2H); 7.63 (m, 2H); 7.8 (d, 2H); 8.49 (s, 1H).
48	[311]	2.73 (s, 3H); 4.49 (d, 2H); 5.31 (t, 1H); 6.44 (d, 1H); 6.97 (d, 1H); 7.18 (m, 1H); 7.48 (m, 1H); 7.55 (m, 1H); 7.6 (m, 2H); 8.46 (s, 1H).
49	[339]	2.72 (s, 3H); 4.49 (m, 2H); 5.31 (m, 1H); 6.44 (d, 1H); 6.99 (d, 1H); 7.41 (m, 1H); 7.51 (m, 1H); 7.65 (m, 2H); 7.77 (m, 1H); 7.82 (m, 1H); 8.5 (s, 1H).
50	[360]	2 (m, 4H); 3.29 (m, 4H); 4.48 (d, 2H); 5.29 (t, 1H); 6.41 (d, 1H); 6.61 (m, 2H); 6.88 (d, 1H); 7.53 (m, 2H); 7.75 (m, 2H); 8.2 (s, 1H); 8.76 (s, 1H).
51	[316]	4.48 (d, 2H); 5.31 (t, 1H); 6.45 (d, 1H); 6.95 (d, 1H); 7.65 (m, 3H); 7.77 (m, 1H); 8.29 (m, 1H); 8.37 (m, 1H); 8.51 (s, 1H); 8.85 (s, 1H).
52	[331]	4.49 (m, 2H); 5.33 (m, 1H); 6.49 (d, 1H); 6.96 (d, 1H); 7.3 (m, 3H); 7.65 (m, 4H); 8.49 (s, 1H); 8.91 (s, 1H).
53	[348]	4.49 (m, 2H); 5.35 (m, 1H); 6.49 (d, 1H); 7.01 (d, 1H); 7.45 (m, 1H); 7.55 (m, 1H); 7.72 (m, 2H); 8.05 (d, 1H); 8.15 (d, 1H); 8.76 (s, 1H); 8.96 (s, 1H).
54	[347]	4.49 (m, 2H); 5.31 (m, 1H); 6.47 (d, 1H); 6.94 (d, 1H); 7.35 (m, 2H); 7.64 (m, 2H); 7.84 (m, 2H); 8 (d, 1H); 8.5 (s, 1H); 8.9 (s, 1H).
55	[352]	4.7 (m, 2H); 5.6 (m, 1H); 7.45 (s, 1H); 7.7 (m, 2H); 7.85 (s, 1H); 8.3 (m, 4H); 8.6 (s, 1H); 8.95 (s, 1H).
56	[313]	4.7 (m, 2H); 5.6 (m, 1H); 7.41 (s, 1H); 7.6 (m, 4H); 7.8 (s, 1H); 7.91 (s, 1H); 8.2 (s, 1H); 8.9 (s, 1H).
57	[353]	2.51 (s, 3H); 4.7 (m, 2H); 5.58 (m, 1H); 7.31 (m, 2H); 7.42 (s, 1H); 7.6 (m, 2H); 7.8 (s, 1H); 7.91 (m, 2H); 8.31 (s, 1H); 8.88 (s, 1H).
58	[347]	4.68 (m, 2H); 5.59 (m, 1H); 7.16 (d, 1H); 7.4 (m, 2H); 7.62 (m, 2H); 7.81 (s, 1H); 8.27 (s, 1H); 8.9 (s, 1H).
59	[385]	3.25 (s, 3H); 4.7 (m, 2H); 5.6 (m, 1H); 7.45 (s, 1H); 7.68 (m, 2H); 7.35 (s, 1H); 7.98 (d, 2H); 8.23 (d, 2H); 8.53 (s, 1H); 8.94 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
60	[363]	4.7 (m, 2H); 5.58 (m, 1H); 7.35 (m, 2H); 7.43 (s, 1H); 7.65 (m, 2H); 7.85 (m, 2H); 7.9 (s, 1H); 7.98 (d, 1H); 8.4 (s, 1H); 8.95 (s, 1H).
61	[363]	4.7 (m, 2H); 5.58 (m, 1H); 7.43 (s, 1H); 7.52 (d, 1H); 7.63 (m, 2H); 7.8 (m, 2H); 7.98 (m, 1H); 8.06 (m, 1H); 8.4 (s, 1H); 8.95 (s, 1H); 8.92 (s, 1H).
62	[322]	2.72 (s, 3H); 4.85 (d, 2H); 6.15 (t, 1H); 7.35 (t, 1H); 7.48 (t, 2H); 7.65 (d, 1H); 7.84 (m, 3H); 8.15 (s, 1H); 8.75 (s, 1H)
63	[328]	2.73 (s, 3H); 4.85 (d, 2H); 6.18 (t, 1H); 7.17 (d, 1H); 7.48 (d, 1H); 7.55 (d, 1H); 7.63 (d, 1H); 7.82 (d, 1H); 8.15 (s, 1H); 8.73 (s, 1H)
64	[352]	2.70 (s, 3H); 3.82 (s, 3H); 4.82 (d, 2H); 6.16 (t, 1H); 7.05 (d, 2H); 7.63 (d, 1H); 7.75 (d, 2H); 7.82 (d, 1H); 8.15 (s, 1H); 8.75 (s, 1H)
65	[377]	1.98 (t, 4H); 3.28 (t, 4H); 4.82 (t, 2H); 6.18 (t, 1H); 6.60 (d, 2H); 7.56 (d, 1H); 7.75 (m, 3H); 8.05 (s, 1H); 8.25 (s, 1H); 9.03 (s, 1H)
66	[326]	4.82 (s, 2H); 6.19 (m, 1H); 7.31 (m, 2H); 7.38 (m, 1H); 7.67 (d, 1H); 7.84 (d, 1H); 8.08 (s, 1H); 8.38 (t, 1H); 8.45 (d, 1H); 9.22 (s, 1H)
67	[386]	3.25 (s, 3H); 4.85 (s, 2H); 6.18 (m, 1H); 7.71 (d, 1H); 7.87 (d, 1H); 8.00 (d, 2H); 8.14 (s, 1H); 8.22 (d, 2H); 8.67 (s, 1H); 9.14 (s, 1H)
68	[348]	4.83 (s, 2H); 6.19 (m, 1H); 7.28 (m, 2H); 7.35 (m, 1H); 7.67 (m, 3H); 7.79 (d, 1H); 8.12 (s, 1H) 8.53 (s, 1H); 9.20 (s, 1H)
69	[364]	4.83 (s, 2H); 6.19 (m, 1H); 7.35 (m, 2H); 7.68 (d, 1H); 7.85 (m, 3H); 7.98 (d, 1H); 8.12 (s, 1H) 8.55 (s, 1H); 9.15 (s, 1H)
70	[298]	4.82 (s, 2H); 6.18 (m, 1H); 6.60 (d, 1H); 6.82 (d, 1H); 7.60 (d, 1H); 7.74 (s, 1H); 7.82 (d, 1H); 8.08 (s, 1H); 8.38 (s, 1H); 9.14 (s, 1H)
71	[364]	4.83 (s, 2H); 6.18 (m, 1H); 7.55 (d, 1H); 7.67 (d, 1H); 7.82 (m, 2H); 7.96 (d, 1H); 8.08 (d, 1H); 8.12 (s, 1H); 8.50 (s, 1H); 8.55 (s, 1H); 9.15 (s, 1H)
72	[376]	2 (m, 4H); 3.32 (m, 4H); 4.68 (d, 2H); 5.58 (t, 1H); 6.6 (d, 2H); 7.41 (s, 1H); 7.55 (m, 2H); 7.75 (m, 3H); 8.11 (s, 1H); 8.82 (s, 1H).
73	181.5-182	1.5 (d, 3H); from 4.95 to 5.05 (m, 1H); 5.65 (d, 1H); 7.45 (s, 1H); 7.55 (d, 2H); from 7.6 to 7.7 (m, 2H); 7.8 (s, 1H); 8.05 (d, 2H); 8.4 (s, 1H); 8.95 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
74	206-210	1.6 (s, 6H); 5.5 (s, 1H); 7.4 (s, 1H); 7.5 (d, 2H); from 7.6 to 7.7 (m, 2H); 7.75 (s, 1H); 8.0 (d, 2H); 8.35 (s, 1H); 8.9 (s, 1H).
75	[335]	2.68 (s, 3H); 3.81 (s, 3H); 4.49 (d, 2H); 5.32 (t, 1H); 6.45 (d, 1H); 6.98 (d, 1H); 7.06 (d, 2H); 7.61 (m, 2H); 7.75 (m, 2H); 8.48 (s, 1H).
76	[358]	4.5 (d, 2H); 5.32 (t, 1H); 6.45 (d, 1H); 6.95 (d, 1H); 7.66 (m, 2H); 7.81 (m, 2H); 8.18 (m, 2H); 8.6 (s, 1H); 8.87 (s, 1H).
77	[321]	3.8 (s, 3H); 4.48 (d, 2H); 5.31 (t, 1H); 6.42 (d, 1H); 6.9 (d, 1H); 7.02 (d, 2H); 7.6 (m, 2H); 7.89 (d, 2H); 8.32 (s, 1H); 8.81 (s, 1H).
78	[308]	4.48 (d, 2H); 5.31 (t, 1H); 6.42 (d, 1H); 6.92 (d, 1H); 7.3 (m, 2H); 7.61 (m, 2H); 7.99 (m, 2H); 8.41 (s, 1H); 8.82 (s, 1H).
79	[327]	4.48 (m, 2H); 5.31 (m, 1H); 6.43 (d, 1H); 6.93 (d, 1H); 7.51 (m, 1H); 7.65 (m, 2H); 7.8 (m, 1H); 7.97 (m, 1H); 8.49 (s, 1H); 8.82 (s, 1H).
80	[297]	4.48 (d, 2H); 5.31 (t, 1H); 6.42 (d, 1H); 6.91 (d, 1H); 7.6 (m, 4H); 7.9 (d, 1H); 8.29 (s, 1H); 8.82 (s, 1H).
81	[331]	4.48 (m, 2H); 5.31 (m, 1H); 6.42 (d, 1H); 6.92 (d, 1H); 7.16 (d, 1H); 7.4 (d, 1H); 7.6 (m, 2H); 8.33 (s, 1H); 8.82 (s, 1H).
82	[309]	4.48 (m, 2H); 5.31 (m, 1H); 6.43 (d, 1H); 6.91 (d, 1H); 7.38 (m, 3H); 7.65 (m, 2H); 8.26 (m, 1H); 8.41 (d, 1H); 8.92 (s, 1H).
83	[369]	4.48 (m, 2H); 5.31 (m, 1H); 6.45 (d, 1H); 6.94 (d, 1H); 7.42 (m, 1H); 7.51 (m, 1H); 7.62 (m, 2H); 7.96 (d, 1H); 8.15 (s, 1H); 8.52 (s, 1H); 8.82 (s, 1H).
84	[339]	2.41 (s, 3H); 4.49 (m, 2H); 5.31 (m, 1H); 6.44 (d, 1H); 6.92 (d, 1H); 7.45 (m, 1H); 7.61 (m, 2H); 7.79 (m, 1H); 7.98 (m, 1H); 8.45 (s, 1H); 8.82 (s, 1H).
85	[369]	3.25 (s, 3H); 4.49 (m, 2H); 5.31 (m, 1H); 6.44 (d, 1H); 6.95 (d, 1H); 7.69 (m, 2H); 8 (d, 2H); 8.21 (d, 2H); 8.62 (s, 1H); 8.87 (s, 1H).
86	[297]	4.48 (m, 2H); 5.31 (m, 1H); 6.44 (d, 1H); 6.91 (d, 1H); 7.12 (m, 1H); 7.51 (m, 2H); 7.6 (m, 2H); 8.32 (s, 1H); 8.81 (s, 1H).
87	[331]	4.49 (m, 2H); 5.31 (m, 1H); 6.45 (d, 1H); 6.92 (d, 1H); 7.41 (m, 2H); 7.66 (m, 3H); 8.19 (m, 1H); 8.51 (s, 1H); 8.56 (s, 1H); 8.88 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
88	[333]	3.25 (t, 2H); 4.49 (m, 2H); 4.58 (t, 2H); 5.31 (m, 1H); 6.45 (d, 1H); 6.82 (d, 1H); 6.9 (d, 1H); 7.57 (m, 2H); 7.7 (d, 1H); 7.81 (s, 1H); 8.29 (s, 1H); 8.8 (s, 1H).
89	[281]	4.49 (d, 2H); 5.31 (t, 1H); 6.45 (d, 1H); 6.6 (m, 1H); 6.83 (d, 1H); 6.91 (d, 1H); 7.61 (m, 2H); 7.76 (s, 1H); 8.25 (s, 1H); 8.88 (s, 1H).
90	[331]	4.49 (m, 2H); 5.31 (m, 1H); 6.45 (d, 1H); 6.91 (s, 1H); 7.02 (s, 1H); 7.61 (m, 3H); 7.91 (d, 1H); 8.01 (s, 1H); 8.25 (s, 1H); 8.45 (s, 1H); 8.85 (s, 1H).
91	[298]	4.48 (m, 2H); 5.31 (m, 1H); 6.44 (d, 1H); 6.94 (d, 1H); 7.67 (m, 2H); 7.75 (d, 1H); 7.91 (d, 1H); 8.52 (s, 1H); 8.91 (s, 1H).
92	[337]	3.32 (s, 3H); 4.48 (m, 2H); 5.31 (m, 1H); 6.44 (d, 1H); 6.91 (d, 1H); 7.32 (d, 2H); 7.6 (m, 2H); 7.8 (m, 2H); 8.41 (s, 1H); 8.81 (s, 1H).
93	[355]	2.72 (s, 3H); 4.7 (d, 2H); 5.59 (t, 1H); 7.52 (d, 2H); 7.62 (m, 3H); 7.85 (m, 3H); 8.6 (s, 1H).
94	[327]	2.76 (s, 3H); 4.68 (d, 2H); 5.58 (t, 1H); 7.18 (m, 1H); 7.48 (d, 1H); 7.57 (m, 3H); 7.62 (m, 1H); 7.86 (s, 1H); 8.58 (s, 1H).
95	[355]	2.72 (s, 3H); 4.68 (d, 2H); 5.58 (t, 1H); 7.41 (m, 1H); 7.51 (m, 1H); 7.65 (m, 3H); 7.79 (d, 1H); 7.86 (m, 2H); 8.61 (s, 1H).
96	[357]	3.3 (s, 3H); 4.69 (m, 2H); 5.59 (m, 1H); 7.21 (m, 1H); 7.39 (m, 1H); 7.66 (m, 4H); 7.88 (s, 1H); 8.6 (s, 1H).
97	[325]	4.68 (m, 2H); 5.57 (m, 1H); 7.28 (m, 2H); 7.41 (s, 1H); 7.61 (m, 2H); 7.81 (s, 1H); 8 (m, 2H); 8.31 (s, 1H); 8.9 (s, 1H).
98	[343]	4.68 (m, 2H); 5.57 (m, 1H); 7.42 (s, 1H); 7.5 (m, 1H); 7.61 (m, 2H); 7.8 (m, 2H); 7.98 (m, 1H); 8.4 (s, 1H); 8.9 (s, 1H).
99	[332]	4.7 (m, 2H); 5.58 (m, 1H); 7.48 (s, 1H); 7.66 (m, 3H); 7.79 (d, 1H); 7.85 (s, 1H); 8.32 (d, 1H); 8.41 (s, 1H); 8.5 (s, 1H); 8.92 (s, 1H).
100	[325]	4.7 (m, 2H); 5.58 (m, 1H); 7.32 (m, 4H); 7.67 (m, 2H); 7.8 (s, 1H); 8.29 (m, 2H); 9 (s, 1H).
101	[384]	4.68 (d, 2H); 5.57 (m, 1H); 7.41 (m, 2H); 7.50 (d, 1H); 7.64 (m, 2H); 7.82 (s, 1H); 7.97 (d, 1H); 8.15 (s, 1H); 8.43 (s, 1H); 8.88 (s, 1H)
102	[347]	4.69 (s, 2H); 5.58 (m, 1H); 7.31 (m, 3H); 7.42 (s, 1H); 7.68 (m, 4H); 7.82 (s, 1H); 8.46 (s, 1H); 8.98 (s, 1H)

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
103	[313]	4.68 (d, 2H); 5.57 (m, 1H); 7.13 (m, 1H); 7.41 (s, 1H); 7.57 (m, 4H); 7.80 (s, 1H); 8.22 (s, 1H); 8.88 (s, 1H)
104	[347]	4.69 (d, 2H); 5.57 (m, 1H); 7.41 (m, 3H); 7.65 (m, 3H); 7.82 (s, 1H); 8.21 (m, 1H); 8.44 (s, 1H); 8.53 (s, 1H); 8.95 (s, 1H)
105	[361]	4.33 (s, 3H); 4.69 (s, 2H); 5.58 (m, 1H); 7.26 (m, 2H); 7.43 (s, 1H); 7.65 (dd, 2H); 7.75 (s, 2H); 7.86 (s, 1H); 8.56 (s, 1H); 9.04 (s, 1H)
106	[349]	3.25 (t, 2H); 4.55 (t, 2H); 4.68 (s, 2H); 5.57 (m, 1H); 6.81 (d, 1H); 7.42 (s, 1H); 7.57 (m, 2H); 7.71 (d, 1H); 7.78 (s, 1H); 7.83 (s, 1H); 8.20 (s, 1H); 8.86 (s, 1H)
107	[297]	4.65 (s, 2H); 5.57 (m, 1H); 6.60 (m, 1H); 6.82 (m, 1H); 7.40 (s, 1H); 7.57 (d, 1H); 7.65 (d, 1H); 7.75 (s, 1H); 7.80 (s, 1H); 8.12 (s, 1H); 8.92 (s, 1H)
108	[347]	4.68 (s, 2H); 5.57 (m, 1H); 7.02 (d, 1H); 7.44 (s, 1H); 7.64 (m, 3H); 7.81 (s, 1H); 7.95 (d, 1H); 8.02 (s, 1H); 8.27 (s, 1H); 8.34 (s, 1H); 8.91 (s, 1H)
109	[314]	4.68 (s, 2H); 5.58 (m, 1H); 7.40 (s, 1H); 7.68 (dd, 2H); 7.75 (d, 1H); 7.83 (s, 1H); 7.92 (d, 1H); 8.40 (s, 1H); 8.98 (s, 1H)
110	[356]	2.70 (s, 3H); 4.82 (s, 2H); 6.18 (m, 1H); 7.54 (d, 2H); 7.65 (d, 1H); 7.85 (m, 3H); 8.17 (s, 1H); 8.75 (s, 1H)
111	[356]	2.72 (s, 3H); 4.82 (s, 2H); 6.19 (m, 1H); 7.42 (d, 1H); 7.52 (t, 1H); 7.67 (d, 1H); 7.78 (d, 1H); 7.85 (m, 2H); 8.16 (s, 1H); 8.77 (s, 1H)
112	[376]	4.81 (s, 2H); 6.19 (m, 1H); 7.68 (d, 1H); 7.82 (m, 3H); 8.10 (s, 1H); 8.15 (d, 2H); 8.62 (s, 1H); 9.12 (s, 1H)
113	[326]	4.81 (s, 2H); 6.19 (m, 1H); 7.29 (t, 2H); 7.65 (d, 1H); 7.81 (d, 1H); 7.99 (m, 2H); 8.10 (s, 1H); 8.47 (s, 1H); 9.11 (s, 1H)
114	[344]	4.81 (s, 2H); 6.19 (m, 1H); 7.52 (q, 1H); 7.65 (d, 1H); 7.80 (m, 1H); 7.82 (d, 1H); 7.96 (m, 1H); 8.12 (s, 1H); 8.52 (s, 1H); 9.10 (s, 1H)
115	[314]	4.81 (s, 2H); 6.19 (m, 1H); 7.60 (m, 3H); 7.79 (d, 1H); 7.90 (d, 1H); 8.07 (s, 1H); 8.32 (s, 1H); 9.09 (s, 1H)
116	[309]	4.82 (s, 2H); 6.20 (m, 1H); 7.32 (m, 1H); 7.67 (d, 1H); 7.83 (d, 1H); 7.87 (t, 1H); 8.10 (m, 2H); 8.59 (m, 2H); 9.20 (s, 1H)

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
117	[348]	4.80 (s, 2H); 6.20 (m, 1H); 7.15 (d, 1H); 7.39 (d, 1H); 7.61 (d, 1H); 7.82 (d, 1H); 8.10 (m, 1H); 8.39 (s, 1H); 9.08 (s, 1H)
118	[385]	4.81 (s, 2H); 6.19 (m, 1H); 7.42 (t, 1H); 7.53 (d, 1H); 7.67 (d, 1H); 7.84 (d, 1H); 7.95 (d, 1H); 8.12 (m, 2H); 8.57 (s, 1H); 9.08 (s, 1H)
119	[356]	2.4 (s, 3H); 4.82 (s, 2H); 6.20 (m, 1H); 7.48 (d, 1H); 7.63 (d, 1H); 7.80 (m, 2H); 7.95 (s, 1H); 8.10 (s, 1H); 8.47 (s, 1H); 9.08 (s, 1H)
120	[314]	4.80 (s, 2H); 6.18 (m, 1H); 7.12 (m, 1H); 7.51 (m, 2H); 7.61 (d, 1H); 7.80 (d, 1H); 8.09 (s, 1H); 8.35 (s, 1H); 9.08 (s, 1H)
121	[347]	4.82 (s, 2H); 6.18 (m, 1H); 7.40 (m, 2H); 7.67 (m, 2H); 7.83 (d, 1H); 8.10 (s, 1H); 8.19 (m, 1H); 8.50 (s, 1H); 8.59 (m, 1H); 9.17 (s, 1H)
122	[350]	3.23 (t, 2H); 4.57 (t, 2H); 4.81 (s, 2H); 6.17 (m, 1H); 6.82 (d, 1H); 7.60 (d, 1H); 7.70 (d, 1H); 7.75 (d, 1H); 7.82 (s, 1H); 8.07 (s, 1H); 8.33 (s, 1H); 9.07 (s, 1H)
123	[348]	4.82 (s, 2H); 6.17 (m, 1H); 7.03 (s, 1H); 7.65 (m, 2H); 7.80 (d, 1H); 7.92 (d, 1H); 8.02 (s, 1H); 8.09 (s, 1H); 8.35 (s, 1H); 8.49 (s, 1H); 9.11 (s, 1H)
124	[315]	4.80 (d, 2H); 6.18 (t, 1H); 7.68 (d, 1H); 7.75 (s, 1H); 7.90 (m, 2H); 8.12 (s, 1H); 8.58 (s, 1H); 9.20 (s, 1H)
125	[321]	4.48 (s, 2H); 4.56 (s, 2H); 5.25 (m, 1H); 5.31 (m, 1H); 6.44 (d, 1H); 6.92 (d, 1H); 7.28 (d, 1H); 7.40 (t, 1H); 7.60 (m, 2H) 7.81 (d, 1H); 7.95 (s, 1H); 8.45 (s, 1H); 8.85 (s, 1H)
126	[376]	1.89 (s, 3H); 4.28 (d, 2H); 4.48 (s, 2H); 5.32 (m, 1H); 6.44 (d, 1H); 6.92 (d, 1H); 7.32 (d, 2H); 7.61 (m, 2H); 7.90 (d, 2H) 8.36 (t, 1H); 8.42 (s, 1H); 8.82 (s, 1H)
127	[380]	2.9 (s, 3H); 3 (s, 3H); 4.5 (s, 2H); 5.3 (s, 1H); 6.45 (d, 1H); 6.95 (d, 1H); 7.45 (t, 1H); 7.65 (m, 2H); 7.85 (m, 2H); 8.55 (s, 1H); 8.85 (s, 1H)
128	182-185	1.55 (s, 6H); 5.5 (s, 1H); 6.45 (s, 1H); 7.4 (m, 2H); 7.6 (m, 4H); 7.7 (s, 1H); 8.05 (s, 1H); 8.3 (s, 1H); 8.9 (s, 1H); 11.15 (s, 1H).
129	[365]	2.07 (s, 3H); 4.31 (m, 2H); 6.18 (m, 1H); 7.38 (m, 1H); 7.59 (m, 3H); 7.67 (d, 1H); 7.85 (d, 1H); 8.11 (s, 1H); 8.21 (s, 1H); 8.42 (s, 1H); 9.15 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
130	[338]	4.53 (m, 2H); 4.82 (m, 2H); 5.21 (m, 1H); 6.18 (m, 1H); 7.41 (d, 2H); 7.69 (m, 1H); 7.9 (m, 3H); 8.12 (s, 1H); 8.5 (s, 1H); 9.12 (s, 1H).
131	[338]	4.59 (d, 2H); 4.83 (d, 2H); 5.28 (t, 1H); 6.19 (t, 1H); 7.29 (d, 1H); 7.4 (m, 1H); 7.65 (d, 1H); 7.8 (m, 2H); 7.94 (s, 1H); 8.1 (s, 1H); 8.48 (s, 1H); 9.1 (s, 1H).
132	[347]	4.82 (m, 2H); 6.19 (m, 1H); 6.52 (s, 1H); 7.4 (m, 1H); 7.5 (d, 1H); 7.7 (m, 2H); 7.91 (m, 1H); 8.15 (m, 2H); 8.48 (s, 1H); 9.2 (s, 1H); 11.2 (s, 1H).
133	[328]	2.25 (s, 3H); 4.81 (m, 2H); 6.18 (m, 1H); 7.1 (s, 1H); 7.35 (s, 1H); 7.61 (d, 1H); 7.81 (d, 1H); 8.1 (s, 1H); 8.32 (s, 1H); 9.11 (s, 1H).
134	[347]	4.85 (m, 2H); 6.2 (m, 1H); 7 (s, 1H); 7.25 (m, 1H); 7.5 (m, 2H); 7.6 (d, 2H); 7.7 (d, 1H); 7.9 (d, 1H); 8.11 (d, 1H); 9.11 (s, 1H); 11.3 (s, 1H).
135	[327]	4.83 (d, 2H); 6.2 (t, 1H); 7.5 (m, 1H); 7.7 (d, 1H); 7.9 (d, 1H); 8.11 (m, 1H); 8.21 (d, 1H); 8.52 (d, 1H); 8.7 (m, 1H); 9.25 (s, 1H).
136	[379]	3 (broad peak, 6H); 4.81 (d, 2H); 6.18 (t, 1H); 7.49 (m, 2H); 7.65 (d, 1H); 7.83 (d, 1H); 8 (d, 2H); 8.11 (s, 1H); 8.52 (s, 1H); 9.11 (s, 1H).
137	[347]	4.83 (d, 2H); 6.18 (t, 1H); 6.43 (s, 1H); 7.4 (m, 1H); 7.6 (m, 3H); 7.85 (m, 1H); 8.02 (s, 1H); 8.11 (s, 1H); 8.48 (s, 1H); 9.15 (s, 1H); 11.3 (s, 1H).
138	[339]	4.09 (s, 3H); 4.81 (d, 2H); 6.18 (t, 1H); 7.1 (m, 1H); 7.63 (d, 1H); 7.81 (d, 1H); 8.09 (s, 1H); 8.18 (m, 1H); 8.55 (m, 2H); 9.21 (s, 1H).
139	[365]	2.8 (d, 3H); 4.81 (m, 2H); 6.18 (m, 1H); 7.69 (d, 1H); 7.9 (m, 3H); 8.05 (m, 2H); 8.11 (s, 1H); 8.48 (m, 1H); 8.58 (s, 1H); 9.12 (s, 1H).
140	[328]	2.48 (s, 3H); 4.81 (d, 2H); 6.18 (t, 1H); 7.18 (m, 1H); 7.62 (d, 1H); 7.82 (m, 2H); 8.09 (s, 1H); 8.3 (s, 1H); 9.18 (s, 1H).
141	[359]	3.83 (s, 3H); 4.82 (m, 2H); 6.21 (m, 1H); 6.55 (d, 1H); 7.4 (d, 1H); 7.58 (d, 1H); 7.75 (d, 2H); 8.02 (m, 1H); 8.18 (m, 2H); 8.55 (s, 1H); 9.2 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
142	[359]	4.82 (m, 2H); 6.18 (m, 1H); 7.6 (m, 1H); 7.79 (d, 1H); 7.9 (m, 2H); 8.06 (d, 1H); 8.12 (m, 1H); 8.52 (s, 1H); 8.95 (m, 1H); 9.11 (s, 1H); 9.21 (s, 1H); 9.35 (d, 1H).
143	[365]	2.08 (s, 3H); 4.82 (m, 2H); 6.18 (m, 1H); 7.29 (m, 1H); 7.55 (d, 1H); 7.68 (d, 2H); 7.85 (d, 2H); 8.11 (s, 1H); 8.42 (s, 1H); 9.11 (s, 1H); 10.1 (s, 1H).
144	[393]	3.2 (m, 4H); 3.75 (m, 4H); 4.82 (m, 2H); 6.2 (m, 1H); 7.06 (d, 1H); 7.65 (m, 1H); 7.8 (d, 2H); 7.85 (m, 1H); 8.12 (m, 2H); 8.4 (m, 1H); 9.11 (m, 1H).
145	[359]	4.82 (m, 2H); 6.18 (m, 1H); 7.85 (m, 2H); 8.18 (m, 3H); 8.6 (m, 2H); 8.81 (d, 1H); 9.11 (s, 1H); 9.25 (s, 1H); 9.45 (s, 1H).
146	[393]	1.12 (d, 6H); 2.62 (m, 1H); 4.82 (d, 2H); 6.18 (t, 1H); 7.35 (m, 1H); 7.61 (m, 3H); 7.81 (d, 1H); 8.09 (s, 1H); 8.26 (s, 1H); 8.42 (s, 1H); 9.12 (s, 1H); 10 (s, 1H).
147	[415]	2.68 (broad peak, 6H); 4.82 (m, 2H); 6.18 (m, 1H); 7.69 (m, 3H); 7.85 (d, 1H); 8.11 (s, 1H); 8.26 (d, 1H); 8.32 (s, 1H); 8.68 (s, 1H); 9.12 (m, 1H).
148	[345]	4.82 (d, 2H); 6.19 (t, 1H); 7.63 (s, 2H); 7.72 (d, 1H); 7.91 (d, 1H); 8.18 (s, 1H); 8.8 (s, 1H); 9.13 (m, 1H).
149	[368]	0.92 (d, 6H); 1.51 (m, 1H); 1.72 (m, 2H); 4.2 (m, 2H); 4.81 (m, 2H); 6.21 (m, 1H); 7.79 (d, 1H); 7.95 (s, 1H); 8.1 (m, 1H); 8.21 (s, 1H); 8.31 (s, 2H); 9.27 (s, 1H).
150	185-190	1.55 (s, 6H); 6.5 (d, 1H); 7.4 (d, 1H); from 7.55 to 7.8 (m, 6H); 8.0 (s, 1H); 8.8 (s, 1H); 11.4 (s, 1H); 12.8 (s, 1H)
151	200-205	1.6 (s, 6H); 5.7 (s, 1H); 6.45 (s, 1H); 7.4 (m, 1H); 7.6 (m, 2H); 7.7 (d, 1H); 7.9 (d, 1H); 8.1 (s, 1H); 8.15 (d, 1H); 8.5 (s, 1H); 8.6 (s, 1H); 9.25 (s, 1H); 11.2 (s, 1H).
152	228-232	1.55 (s, 6H); 5.35 (s, 1H); 6.45 (s, 1H); 7.4 (t, 1H); 7.45 (d, 1H); 7.65 (m, 2H); 7.7 (d, 1H); 8.0 (d, 1H); 8.1 (m, 2H); 8.45 (s, 1H); 8.6 (d, 1H); 9.3 (s, 1H); 11.2 (s, 1H).

Ex	Mp or [M+H]	¹ H NMR spectrum (DMSO-d ₆ , δ in ppm)
153	255-259	1.5 (s, 6H); 5.35 (s, 1H); 7.25 (t, 1H); 7.4 (t, 1H); 7.45 (d, 1H); 7.6 (d, 1H); 7.75 (d, 1H); 8.05 (m, 2H); 8.5 (d, 1H); 8.55 (s, 1H); 8.65 (d, 1H); 9.4 (s, 1H); 13.15 (s, 1H)
154	195-198	1.55 (s, 6H); 2.5 (s, 3H); 5.35 (s, 1H); 6.7 (s, 1H); 7.5 (m, 1H); 7.75 (d, 1H); 8.05 (m, 2H); 8.55 (s, 1H); 8.65 (d, 1H); 9.4 (s, 1H).
155	263-266	3.7 (s, 3H); 4.55 (d, 2H); 5.35 (t, 1H); 6.45 (m, 1H); 7.05 (s, 1H); 7.35 (d, 1H); 7.4 (m, 1H); 7.65 (m, 3H); 8.05 (s, 1H); 8.35 (s, 1H); 8.65 (s, 1H); 11.15 (s, 1H).
156	210-210.5 (dec)	1.55 (s, 6H); 5.2 (s, 1H); 6.35 (d, 1H); 6.9 (d, 1H); 7.55 (d, 2H); 7.65 (m, 2H); 8.0 (d, 2H); 8.5 (s, 1H); 8.85 (s, 1H).

The compounds according to the invention were the subject of pharmacological tests for determining their modulatory effect on NOT.

Evaluation of the *in vitro* activity on N2A cells

- 5 The activity of the compounds according to the invention was evaluated on a cell line (N2A) endogenously expressing the mouse Nurrl receptor and stably transfected with the NOT binding response element (NBRE) coupled to the luciferase reporter gene. The EC₅₀ values are between 0.1 nM and 10 μM. The tests were carried out according to the procedure described below.
- 10 The Neuro-2A cell line comes from a standard commercial source (ATCC). The Neuro-2A clone was obtained from a spontaneous tumour originating from a mouse A albino strain by R.J Klebe et al. This Neuro-2A line is subsequently stably transfected with 8NBRE-luciferase. The N2A-8NBRE cells are cultured to confluence in 75 cm² culture flasks containing DMEM supplemented with 10% of foetal calf serum, 4.5 g/l of glucose and
- 15 0.4 mg/ml of Geneticin. After one week of culture, the cells are recovered with 0.25% trypsin for 30 seconds and then resuspended in DMEM without phenol red, containing 4.5 g/l of glucose, 10% of Hyclone defatted serum, and deposited in white, transparent-bottom, 96-well plates. The cells are deposited at a rate of 60 000 per well in 75 μl for 24 hours before the addition of the products. The products are applied in 25 μl and
- 20 incubated for a further 24 hours. On the day of the measurement, an equivalent volume

(100 μ l) of Steadylite is added to each well, followed by a waiting period of 30 minutes in order to obtain complete lysis of the cells and maximum production of the signal. The plates are then measured in a microplate luminescence counter after having been sealed with an adhesive film. The products are prepared in the form of a stock solution at 10^{-2} M, and then
5 diluted in 100% of DMSO. Each product concentration is diluted beforehand in culture medium before incubation with the cells thus containing a final concentration of 0.625% of DMSO.

For example, compounds Nos 4, 10, 30, 36, 59 and 64 showed an EC_{50} of 4.5; 2; 48; 137; 74 and 102 nM, respectively.

10 It therefore appears that the compounds according to the invention have a NOT-modulating effect.

The compounds according to the invention can therefore be used for the preparation of medicaments for their therapeutic use in the treatment and prevention of diseases involving NOT receptors.

15 Thus, according to another of its aspects, a subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid.

These medicaments are of use in therapeutics, in particular in the treatment and prevention of neurodegenerative diseases such as, for example, Parkinson's disease, Alzheimer's
20 disease, tauopathies (for example, progressive supranuclear paralysis, frontotemporal dementia, corticobasal degeneration, Pick's disease); cerebral traumas such as ischaemia and cranial traumas and epilepsy, psychiatric diseases such as schizophrenia, depression, substance dependence, attention deficit hyperactivity disorders; inflammatory diseases of the central nervous system, such as multiple sclerosis, encephalitis, myelitis and
25 encephalomyelitis and other inflammatory diseases such as vascular pathologies, atherosclerosis, joint inflammations, arthritis, rheumatoid arthritis, osteoarthritis, Crohn's disease, ulcerative colitis; allergic inflammatory diseases such as asthma, autoimmune diseases such as type 1 diabetes, lupus, scleroderma, Guillain-Barré syndrome, Addison's disease and other immunomediated diseases; osteoporosis; cancers.

30 These compounds could also be used as a treatment combined with stem cell transplantations and/or grafts.

According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active ingredient, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound

2009253232 30 May 2013

WO 2009/144392

68

PCT/FR2009/000298

according to the invention, or a pharmaceutically acceptable salt of said compound, and also at least one pharmaceutically acceptable excipient.

Said excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.

5 In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or salt thereof, may be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to humans for the prophylaxis or the treatment of the disorders or
10 diseases above.

The suitable unit administration forms comprise oral administration forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for
15 administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants. For topical application, the compounds according to the invention may be used in creams, gels, ointments or lotions.

By way of example, a unit administration form of a compound according to the invention in tablet form may comprise the following components:

Compound according to the invention	50.0 mg
20 Mannitol	223.75 mg
Sodium croscarmellose	6.0 mg
Maize starch	15.0 mg
Hydroxypropylmethylcellulose	2.25 mg
Magnesium stearate	3.0 mg

25 There may be particular cases where higher or lower dosages are appropriate; such dosages do not depart from the context of the invention. According to the usual practice, the dosage appropriate for each patient is determined by the physician according to the method of administration and the weight and response of said patient.

30 Also described is a method for treating the pathologies indicated above, which comprises the administration, to

2009253232 30 May 2013

WO 2009/144392

68a

PCT/FR2009/000298

a patient, of an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt thereof.

5 In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

10 In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

2009253232 30 May 2013


WO 2009/144392

69

PCT/FR2009/000298

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

- 5 1. Compounds of formula (I):



in which:

R₁ represents:

- 10 a phenyl or naphthyl group, a heteroaryl group or a heterocyclic group, it being possible for these groups to be optionally substituted with one or more atoms or groups chosen, independently of one another, from the following atoms or groups: halogen, (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, (C₁-C₁₀)thioalkyl, -S(O)(C₁-C₁₀)alkyl, -S(O)₂(C₁-C₁₀)alkyl, hydroxyl, oxo, cyano, nitro, hydroxy(C₁-C₁₀)alkylene, NRaRb(C₁-C₁₀)alkylene, (C₁-C₁₀)alkoxy(C₁-C₁₀)alkyleneoxy, NRaRb, CONRaRb, SO₂NRaRb, NRcCORd, OC(O)NRaRb, OCO(C₁-C₁₀)alkyl, NRcC(O)Ore, NRcSO₂Re, aryl(C₁-C₁₀)alkylene, monocyclic heteroaryl or aryl, the monocyclic heteroaryl or aryl being optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, oxo, nitro, cyano or OCO(C₁-C₁₀)alkyl group, and R₁ is linked to the imidazo[1,2-*a*]pyridine by an aromatic carbon;

25 Het represents a monocyclic heteroaryl group containing from 5 to 6 atoms, including from 1 to 3 heteroatoms chosen from N, O and S;

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen, (C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, NRaRb, nitro and cyano, it being possible for the (C₁-C₁₀)alkyl to be optionally substituted with one or more groups chosen from a halogen, (C₁-C₁₀)alkoxy, (C₁-C₁₀)haloalkoxy, NRaRb or hydroxyl;

2009253232 30 May 2013

WO 2009/144392

70

PCT/FR2009/000298

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen, (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl and (C₁-C₁₀)alkoxy;

R₂ and R₃ represent, independently of one another,

- 5 a hydrogen atom,
 a (C₁-C₁₀)alkyl group, optionally substituted with an R_f group;
 an aryl group, optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro or cyano group;

10 R₄ represents:

- a hydrogen atom,
 a (C₁-C₁₀)alkyl group, optionally substituted with an R_f group;
 an aryl group, optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy,
15 NRaRb, hydroxyl, nitro, cyano, (C₁-C₁₀)alkyl(CO)-, CONRaRb, NRcCORd, OC(O)NRaRb, OCO(C₁-C₁₀)alkyl, NRcC(O)ORe or aryl group, the aryl being optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro or cyano group;

20 Ra and Rb represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl, aryl(C₁-C₁₀)alkylene or aryl group;

or Ra and Rb form, together with the nitrogen atom which bears them, an azetidine, pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted with a (C₁-C₁₀)alkyl,
25 aryl or aryl (C₁-C₁₀)alkylene group;

Rc and Rd represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl, aryl(C₁-C₁₀)alkylene or aryl group;

or Rc and Rd together form a (C₂-C₅)alkylene group;

Re represents a (C₁-C₁₀)alkyl, aryl (C₁-C₁₀)alkylene or aryl group;

30 or Rc and Re together form a (C₂-C₅)alkylene group;

R_f represents a halogen atom or a (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, hydroxyl, cyano, NRaRb, C(O)NRaRb, NRcCORd, OC(O)NRaRb, OCO(C₁-C₁₀)alkyl, NRcCOORe, SO₂NRaRb, NRcSO₂Re, aryl(C₁-C₁₀)alkylene or aryl group, the aryl being optionally substituted with one or more substituents chosen from a halogen and a (C₁-C₁₀)alkyl,

30 May 2013

2009253232

WO 2009/144392

71

PCT/FR2009/000298

halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, halo(C₁-C₁₀)alkoxy, NRaRb, hydroxyl, nitro, cyano or OCO(C₁-C₁₀)alkyl group;

in the form of a base or of an addition salt with an acid.

5 2. Compounds of formula (I) according to Claim 1, wherein:

R₁ represents a phenyl, furyl, quinoliny, indolyl, pyrrolopyridinyl, pyridinyl, isoquinoliny, thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more groups or atoms chosen, independently of one another, from halogen, (C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, CONRaRb, NRaRb, (C₁-C₁₀)thioalkyl, -S(O)₂(C₁-C₁₀-alkyl), halo(C₁-C₁₀)alkyl, hydroxy(C₁-C₁₀)alkylene, NRaRb(C₁-C₁₀)alkylene, NRcCORd, SO₂NRaRb, cyano and nitro;

Ra and Rb represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group;

Rc and Rd represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group.

15

3. Compounds of formula (I) according to Claim 1 or 2, wherein:

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a halogen and (C₁-C₁₀)alkyl groups.

20 4. Compounds of formula (I) according to any one of the preceding claims, wherein:

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-a]pyridine, from 1 to 4 substituents, which are identical to or different from one another, chosen from hydrogen and (C₁-C₁₀)alkyl.

5. Compounds of formula (I) according to any one of the preceding claims, wherein:

25 R₂ and R₃ represent, independently of one another, a hydrogen atom or a (C₁-C₁₀)alkyl group.

6. Compounds of formula (I) according to any one of the preceding claims, wherein:

R₄ represents a hydrogen atom or a (C₁-C₁₀)alkyl group.

2009253232 30 May 2013

WO 2009/144392

72

PCT/FR2009/000298

7. Compounds of formula (I) according to any one of the preceding claims, wherein:

R₁ represents a phenyl, furyl, quinolinyl, indolyl, pyrrolopyridinyl, pyridinyl, isoquinolinyl, thienyl, benzofuranyl, benzothiazolyl, benzothienyl, dihydrobenzofuranyl, thiazolyl, pyrazolyl, isoxazolyl, benzimidazolyl or indazolyl group, it being possible for these groups to be optionally substituted with one or more atoms or groups chosen, independently of one another, from halogen, methyl, methoxy, hydroxymethyl, -CON(CH₃)₂, morpholinyl, pyrrolidinylethyl, -NHCO-CH(CH₃)₂, -CH₂N(CH₃)₂, -NH₂, -CONHCH(CH₃)₂, pyrrolidinyl, methylsulphonyl, trifluoromethyl, methylthio, cyano, nitro, -NHCO(CH₃), CONH(CH₃), CONHC(CH₃)₃, -SO₂N(CH₃)₂ and *isopentyl*;

Het represents a furyl, thienyl, pyridinyl, thiazolyl, pyrazolyl or imidazolyl group;

X represents from 1 to 3 substituents, which are identical to or different from one another, chosen from a hydrogen, a fluorine and a methyl group;

R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-*a*]pyridine, from 1 to 4 hydrogen atoms or methyl groups;

R₂ and R₃ represent, independently of one another, a hydrogen atom or a methyl group;

R₄ represents: a hydrogen atom or a methyl group;

in the form of a base or of an addition salt with an acid.

8. Compounds of formula (I) according to Claim 7, wherein R represents, at position 3 of the imidazo[1,2-*a*]pyridine, 1 hydrogen atom or 1 methyl group.

9. Compounds of formula (I) according to Claim 1, wherein:

R₁ represents a phenyl, furyl or quinolinyl group, it being possible for these groups to be optionally substituted with one or more atoms or groups chosen, independently of one another, from halogen and (C₁-C₁₀)alkyl;

Het represents a furyl group, a thienyl group, a pyridinyl group or a thiazolyl group;

X represents a hydrogen;

R is a hydrogen;

R₂ and R₃ represent, independently of one another, a hydrogen atom;

R₄ represents a hydrogen atom,

in the form of a base or of an addition salt with an acid.

2009253232 30 May 2013

WO 2009/144392

73

PCT/FR2009/000298

10. A compound selected from:

- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {2-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-3-yl}methanol;
- {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {6-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-2-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-3-yl}methanol;
- {2-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-5-yl}methanol;
- {2-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-4-yl}methanol;
- {4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [2-(2-Furan-3-ylimidazo[1,2-*a*]pyridin-6-yl)pyridin-4-yl]methanol and the hydrochloride thereof;
- [5-(2-Quinolin-3-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol and the hydrochloride thereof;
- [4-(2-*p*-Tolylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [2-(2-Quinolin-3-ylimidazo[1,2-*a*]pyridin-6-yl)pyridin-4-yl]methanol and the hydrochloride thereof;
- [4-(2-Quinolin-3-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol and the hydrochloride thereof;
- {4-[2-(1*H*-Indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {5-[2-(1*H*-Indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol and the hydrochloride thereof;
- [4-(2-Phenylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol and the hydrochloride thereof;

2009253232 30 May 2013

WO 2009/144392

74

PCT/FR2009/000298

- {4-[2-(1*H*-Pyrrolo[2,3-*b*]pyridin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol and the hydrochloride thereof;
- {4-[2-(3-Methoxyphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol and the hydrochloride thereof;
- {2-[2-(1*H*-Pyrrolo[2,3-*b*]pyridin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}methanol and the hydrochloride thereof;
- [2-(2-Phenylimidazo[1,2-*a*]pyridin-6-yl)pyridin-4-yl]methanol;
- [5-(2-*p*-Tolylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Phenylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(3-Methoxyphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(2,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-3-yl}methanol;
- 2-(4-Chlorophenyl)-6-(4-methoxymethyl-furan-2-yl)imidazo[1,2-*a*]pyridine;
- {5-[2-(4-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- 4-[6-(5-Hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {5-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(2-Methoxypyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Quinolin-5-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(4-Morpholin-4-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Isoquinolin-5-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- (5-{2-[4-(1-Pyrrolidin-1-ylethyl)phenyl]imidazo[1,2-*a*]pyridin-6-yl}furan-2-yl)methanol;
- 4-[6-(5-Hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {4-[2-(2-Methoxypyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;

2009253232 30 May 2013

WO 2009/144392

75

PCT/FR2009/000298

- [4-(2-Isoquinolin-5-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- *N*-{3-[6-(5-Hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl}isobutyramide;
- (4-{2-[4-(1-Pyrrolidin-1-ylethyl)phenyl]imidazo[1,2-*a*]pyridin-6-yl}thien-2-yl)methanol;
- {4-[2-(4-Dimethylaminomethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- 2-Fluoro-4-[6-(5-hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {4-[2-(3-Aminophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- *N*-tert-Butyl-5-[6-(5-hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]nicotinamide;
- [5-(3-Methyl-2-phenylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(3-Methyl-2-thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(3-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Pyrrolidin-1-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- 3-[6-(5-Hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]benzonitrile;
- [5-(2-Benzofuran-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzothiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzo[b]thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {4-[2-(4-Nitrophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Thien-3-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(4-Methylthiophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(5-Chlorothien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- {4-[2-(4-Methylsulphonylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- [4-(2-Benzo[b]thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;

2009253232 30 May 2013

WO 2009/144392

76

PCT/FR2009/000298

- [4-(2-Benzo[b]thien-5-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(3-Methyl-2-phenylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(3-Methyl-2-thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(4-Methoxyphenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Pyrrolidin-1-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Methylsulphonylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Benzofuran-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Benzo[b]thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Furan-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Benzo[b]thien-5-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(4-Pyrrolidin-1-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}methanol;
- 1-{4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}ethanol;
- 2-{4-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}propan-2-ol;
- {5-[2-(4-Methoxyphenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Trifluoromethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Methoxyphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(3,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- [5-(2-Thien-3-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(5-Chlorothien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(3-Bromophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- {5-[2-(4-Chloro-3-methylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;

2009253232 30 May 2013

WO 2009/144392

77

PCT/FR2009/000298

- {5-[2-(4-Methylsulphonylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl} methanol;
- [5-(2-Thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzofuran-3-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(2,3-Dihydrobenzofuran-5-yl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl} methanol;
- [5-(2-Furan-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Benzofuran-5-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- [5-(2-Thiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)furan-2-yl]methanol;
- {5-[2-(4-Methylthiophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl} methanol;
- {4-[2-(4-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- [4-(3-Methyl-2-thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(3-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- {4-[2-(2,4-Difluorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- {4-[2-(4-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- {4-[2-(3,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- 3-[6-(5-Hydroxymethylthien-3-yl)imidazo[1,2-*a*]pyridin-2-yl]benzonitrile;
- {4-[2-(2-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- {4-[2-(3-Bromophenyl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- [4-(2-Benzofuran-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Benzofuran-3-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(1-Methyl-1*H*-benzimidazol-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;
- {4-[2-(2,3-Dihydrobenzofuran-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl} methanol;

2009253232 30 May 2013

WO 2009/144392

78

PCT/FR2009/000298

- [4-(2-Furan-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Benzofuran-5-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- [4-(2-Thiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)thien-2-yl]methanol;
- {4-[2-(4-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(3-Chlorophenyl)-3-methylimidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Trifluoromethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Fluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(3,4-Difluorophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Thien-3-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Pyridin-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(5-Chlorothien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(3-Bromophenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- {4-[2-(4-Chloro-3-methylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Thien-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Benzofuran-3-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {4-[2-(2,3-Dihydrobenzofuran-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl}methanol;
- [4-(2-Benzofuran-5-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- [4-(2-Thiazol-2-ylimidazo[1,2-*a*]pyridin-6-yl)thiazol-2-yl]methanol;
- {5-[2-(3-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}methanol;
- *N*-{3-[6-(5-Hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl}isobutyramide;
- 2-Fluoro-4-[6-(5-hydroxymethylfuran-2-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- 2-{4-[2-(1H-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]thien-2-yl}propan-2-ol;

2009253232 30 May 2013

WO 2009/144392

79

PCT/FR2009/000298

- *N*-{3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl} acetamide;
- {4-[2-(4-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(3-Hydroxymethylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(1*H*-Indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(4-Methylthien-2-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(1*H*-Indol-4-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(2-Fluoropyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- 3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzamide;
- {4-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(2-Methoxypyridin-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- 4-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N*-methylbenzamide;
- {4-[2-(4-Methylthien-3-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- {4-[2-(1-Methyl-1*H*-indol-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- [4-(2-Quinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]-thiazol-2-yl} methanol;
- *N*-{4-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl} acetamide;
- {4-[2-(4-Morpholin-4-ylphenyl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- [4-(2-Isoquinolin-5-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;
- *N*-{3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]phenyl} isobutyramide;
- 3-[6-(2-Hydroxymethylthiazol-4-yl)imidazo[1,2-*a*]pyridin-2-yl]-*N,N*-dimethylbenzenesulphonamide;
- {4-[2-(2,6-Difluoropyridin-4-yl)imidazo[1,2-*a*]pyridin-6-yl]thiazol-2-yl} methanol;

2009253232 30 May 2013

WO 2009/144392

80

PCT/FR2009/000298

- (4-{2-[1-(3-Methylbutyl)-1*H*-pyrazol-4-yl]imidazo[1,2-*a*]pyridin-6-yl}thiazol-2-yl)methanol;
- 2-{4-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]-1*H*-pyrazol-3-yl}propan-2-ol;
- 2-{5-Fluoro-2-[2-(1*H*-indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- 2-{2-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- 2-{2-[2-(1*H*-Indazol-3-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- 2-{2-[2-(5-Methylisoxazol-3-yl)imidazo[1,2-*a*]pyridin-6-yl]pyridin-4-yl}propan-2-ol;
- {5-[2-(1*H*-Indol-6-yl)imidazo[1,2-*a*]pyridin-6-yl]-1-methyl-1*H*-imidazol-2-yl}methanol; and
- 2-{5-[2-(4-Chlorophenyl)imidazo[1,2-*a*]pyridin-6-yl]furan-2-yl}propan-2-ol.

11. Medicament, comprising a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid.

5 12. Pharmaceutical composition, comprising a compound of formula (I) according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

10 13. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of neurodegenerative diseases.

15 14. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of cerebral traumas and of epilepsy.

2009253232 30 May 2013

WO 2009/144392

81

PCT/FR2009/000298

15. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of psychiatric diseases.


5 16. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of inflammatory diseases.

10 17. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of osteoporosis and cancers.

15 18. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of Parkinson's disease, Alzheimer's disease, tauopathies and multiple sclerosis.

20 19. Use of a compound of formula (I) according to any one of Claims 1 to 10, or an addition salt of this compound with a pharmaceutically acceptable acid, for the preparation of a medicament for use in the treatment and prevention of schizophrenia, depression, substance dependence and attention deficit hyperactivity disorders.

20. Process for synthesizing the compounds of formula (I) according to claim 1 by reacting compounds of formula (VII)



30 May 2013
2009253232


WO 2009/144392

82


PCT/FR2009/000298

in which R6 represents an OPG group, R2, R3, Het, X and R are as defined in Claim 1, and PG is a group protecting the hydroxyl function, with R1-Z, with R1 being as defined in Claim 1 and Z being a boron or tin derivative, and then deprotecting the product obtained.

- 5 21. Process for synthesizing the compounds of formula (VII) according to claim 20 by reacting compounds of formula (V)




in which Y is a boron derivative, and R is as defined in Claim 1, with a compound of formula (VI)




10 in which R6 represents an OPG group, R2, R3, Het and X are as defined in Claim 1, and PG is a group protecting the hydroxyl function.

22. Process for synthesizing the compounds of formula (I) by reacting compounds of formula (II)



15 in which R and R1 are as defined in Claim 1, and Y is a boron derivative, with a compound of formula (III)



20 in which R5 represents a group and R2, R3, R4, Het and X are as defined in Claim 1 and Z is a halogen.


2009253232 30 May 2013

WO 2009/144392


83

PCT/FR2009/000298

23. Process for synthesizing the compounds of general formula (I) according to Claim 1, wherein an aminopyridine of general formula (XI),



- 5 in which R2, R3, R4, Het and X are defined according to Claim 1, and R6 represents R4, is reacted with a bromoketone of general formula (XII),




in which R1 is defined according to Claim 1 and R represents a hydrogen atom or a (C₁-C₁₀)alkyl group.


10

24. Process for synthesizing the compounds of general formula (I) according to Claim 1, wherein:

a) an aminopyridine of general formula (XI),



- 15 in which R2, R3, R4, Het and X are defined according to Claim 1, and R6 represents R4, is reacted with a bromoketone of general formula (XII),




in which R1 is defined according to Claim 1 and R represents a hydrogen atom or a (C₁-C₁₀)alkyl group, so as to obtain a compound of general formula (XIII)

2009253232 30 May 2013

WO 2009/144392

84

PCT/FR2009/000298



in which R₆ represents a group PG protecting the hydroxyl function;

b) the compound of general formula (XIII) obtained in step a) is subjected to a deprotection reaction.

5









2009253232 30 May 2013

WO 2009/144392


85

PCT/FR2009/000298

25. A compound selected from:



and



2009253232 30 May 2013

WO 2009/144392

86

PCT/FR2009/000298

5

26. Synthesis process according to any one of Claims 20 to 24, wherein the compounds of general formulae (II), (V), (VII) and (X) are the compounds of general formulae (II-1), (II-2), (II-3), (II-4), (II-5), (II-6), (II-7), (V-1), (VII-1), (VII-2), (VII-3), (VII-4), (X-1), (X-2), (X-3) and (X-4)

